The Role of Chemokines in Obesity and Exercise-Induced Weight Loss.

1. Introduction

Obesity has become a major public health challenge globally, and according to the World Health Organization (WHO), approximately 1.9 billion adults are overweight, with more than 650 million of them being obese. Obesity rates are projected to exceed 18 per cent for men and 21 per cent for women by 2025 [ 1 ]. In European countries such as Cyprus and Lithuania, childhood obesity is prominently evidenced by significant rates of overweight or obesity [ 2 , 3 ]. By 2030, it is expected that 45 million children over the age of 5 will be obese in South and Southeast Asia. Meanwhile, China’s obesity rate is also rising to varying degrees among both urban and rural populations, predicting a significant increase in obesity rates among both adults and children [ 4 , 5 , 6 ]. Obesity is strongly associated with a wide range of chronic diseases, including cardiovascular disease, diabetes, atherosclerosis, dyslipidemia, and hypertension, exacerbating the public health burden. Therefore, effective interventions are urgently needed [ 7 , 8 , 9 ].

Chemokines are a class of signaling molecules that regulate the aggregation of cells towards sites of inflammation and play a key role in macrophage infiltration of adipose tissue. In adipose tissues, the high expression of chemokines significantly impacts the formation and development of obesity-related conditions. For instance, C-C motif chemokine ligand 2 (CCL2) and C-C motif chemokine ligand 5 (CCL5) are closely associated with obesity-induced cardiovascular disease and insulin resistance [ 10 , 11 , 12 ]. Research has indicated that genetic knockout or pharmacological inhibition of chemokine pathways have improved glucose tolerance, insulin sensitivity, hyperlipidemia, and steatohepatitis in mice [ 13 , 14 , 15 ]. Moreover, downregulating chemokines and their receptors can decrease the inflammatory responses induced by obesity, prevent the onset of insulin resistance, and facilitate the upregulation of mitochondrial oxidative phosphorylation and fatty acid metabolism pathways, for example, in brown adipocytes as seen with CCL5 [ 16 , 17 ]. In addition, the inhibition of chemokines suppresses the inflammatory response in the liver and adipose tissue, reduces the number of immune cells, decreases circulating cytokine levels, and limits adipogenesis and fatty acid uptake. These effects work together to reduce hepatic fat deposition, improve insulin sensitivity, and help reduce obesity symptoms [ 18 , 19 ]. Thus, the development of regulatory strategies targeting chemokines offers a promising avenue for ameliorating obesity.

For example, running has been observed to attenuate inflammatory responses induced by a high-fat diet (HFD) in mice with obesity, subsequently impacting obesity metrics [ 20 ]. High-Intensity Interval Training (HIIT) not only significantly increases the expression of C-C chemokine receptor type 5 (CCR5) in immune cells but also decreases levels of inflammatory mediators such as the Interleukin-6 (IL-6) receptor and Monocyte Chemotactic Protein-1 (MCP-1) in plasma and adipose tissue, potentially ameliorating health issues associated with overweight and obesity. Meanwhile, Moderate Intensity Continuous Training (MICT) has been shown to reduce the expression of C-C chemokine receptor type 2 (CCR2) and C-X-C chemokine receptor type 2 (CXCR2), further confirming that the type and intensity of exercise directly regulate immune cell function and inflammatory states [ 21 , 22 ]. In addition, studies have also shown that exercise improves the vascular repair capacity of Endothelial progenitor cells (EPCs) in older adults by enhancing the C-X-C chemokine receptor type 4 (CXCR4)/ Janus kinase-2 (JAK-2) signaling pathway, revealing a potential mechanism of exercise as a potential mechanism of anti-aging strategy [ 23 ].

Vigorous exercise mobilizes specific monocyte subpopulations through a catecholamine-dependent mechanism, in particular a significant increase in the number of CD14 + CD16 + monocytes [ 24 ]. Meanwhile, acute exercise-induced changes in cortisol regulate the expression and migratory activity of monocyte CCR2, affecting the inflammatory response and tissue repair [ 25 ]. Exercise activates the transcription factor 3 (ATF3) , which reduces chemokine and cytokine expression in mouse skeletal muscle; this supports molecular adaptations to endurance training [ 26 ]. The aim of this paper is to explore how exercise adjusts chemokine expression to improve the health of obese patients and reveal its potential therapeutic role in weight loss and tissue repair. We also highlight the need for an in-depth exploration of the mechanisms by which exercise affects chemokine-mediated pathways.

2. Obesity Overview

Obesity is defined as a chronic condition with body mass index (BMI) ≥ 30 kg/m 2 , caused by multiple factors such as genetics, environmental factors, poor dietary patterns, sedentary lifestyle, and endocrine disorders [ 7 , 27 , 28 , 29 , 30 ]. Obesity triggers Nonalcoholic Steatohepatitis (NASH). It causes liver fat accumulation, inflammation, and fibrosis through increased serum Lipopolysaccharide (LPS) levels and activation of toll-like receptor 4 (TLR4) pathway, which severely impairs liver function and overall health. Obesity also increases the risk of hypertension, dyslipidemia, and other cardiovascular diseases in children in adulthood [ 31 , 32 ]. In addition, obesity not only leads to excessive accumulation of liver fat, but also triggers the risk of cancers, and may lead to a poor cancer prognosis [ 27 ]. Based on BMI, obesity can be categorized into three grades: Grade I (30.0–34.9), Grade II (35.0–39.9), and Grade III (40.0 and above) [ 7 ], Figure 1 .

In terms of metabolic health, people who are obese or overweight have a 1.74 times higher risk of cardiovascular disease compared to those of normal weight. Obesity is strongly associated with high blood pressure. Obesity causes chronic low-grade inflammation of visceral adipose tissue, which increases the risk of cardiovascular and metabolic diseases and affects vascular function, increasing the risk of developing hypertension [ 33 , 34 ].

Moreover, obesity is strongly associated with the risk of developing Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS). Individuals with obesity have a higher likelihood of suffering from this condition, which can potentially lead to insulin resistance and glucose metabolism disorders [ 35 ]. Women with central obesity and metabolic syndrome are also at risk of developing sleep apnea OSAHS [ 36 ]. Specifically, the degree of obesity is positively associated with the severity of OSAHS, which has important implications for both sleep and breathing [ 37 , 38 ]. Systemic chronic inflammation due to obesity may result in insulin resistance and impaired pancreatic β-cell function, increasing the risk for type 2 diabetes [ 9 ].

In addition, obesity is positively associated with the risk of gout and hyperuricemia, with the prevalence of disease increasing with weight gain [ 39 ]. Genetic factors and higher BMI significantly increased the risk of gout, with each standard deviation increase in BMI significantly increasing the risk of gout and serum uric acid concentration. The significant association between obesity and gout risk was confirmed even after adjusting for waist-to-hip ratio [ 40 ]. Obesity not only puts children at risk of osteoporosis and chronic inflammation, but may also increase the risk of cardiovascular disease, while being associated with metabolic syndrome and its concomitant multiple cardiometabolic risk factors [ 9 , 41 ]. Obesity not only affects an individual’s quality of life, but also significantly increases the risk of developing a wide range of chronic diseases, making the prevention and treatment of obesity an urgent public health challenge.

3. Chemokine Overview

Chemokines are a class of small molecule proteins that play a key role in immune responses and regulate inflammatory and immune processes by directing immune cell migration. Regarding the current chemokine nomenclature system, human chemokines are mainly used as the standard for categorization and nomenclature [ 42 ]. Chemokines are small molecule proteins with molecular weights between 8 and 14 kDa. They play a pivotal role in immune function by regulating the migration of various leukocytes through interactions with G protein-coupled receptors (GPCR) [ 42 , 43 ]. In humans , approximately 50 chemokines have been identified [ 44 ]. These chemokines are classified into four main families based on their structural features: CXC, CC, XC, and CX3C [ 42 , 45 , 46 , 47 ]. Upon binding to their corresponding receptors, chemokines activate intracellular signaling pathways that regulate cell migration, proliferation, survival, and differentiation. Chemokines are essential for the maintenance of immune system development, homeostasis and function by directing immune directed migration. About 20 chemokine receptors have been identified, including C-C chemokine receptor type 1 (CCR1) to C-C chemokine receptor type 9 (CCR9), C-X-C chemokine receptor type 1 (CXCR1) to C-X-C chemokine receptor type 8 (CXCR8), X-C motif chemokine receptor 1 (XCR1), C-X3-C Motif Chemokine Receptor 1 (CX3CR1), which all belong to the GPCR family [ 42 , 44 , 48 , 49 ]. The role of chemokines and their receptors in a variety of diseases suggests that they may be potential targets for the treatment of a number of diseases, including obesity ( Table 1 and Table 2 ).

3.1. CXC Chemokines

CXC chemokines are a class of cytokines with specific structural features that play important roles in immune and inflammatory responses. CXC chemokines constitute a subclass of cytokines distinguished by the presence of two cysteine residues at the N-terminus separated by a single amino acid [ 42 , 45 ]. These chemokines are composed of four cysteine residues and can be further subdivided based on the presence or absence of the glutamate-leucine-arginine (ELR) motif adjacent to the first cysteine residue. The ELR-positive CXC chemokines primarily recruit neutrophils, while the ELR-negative chemokines are more chemotactic for lymphocytes [ 46 ]. The CXC chemokine family encompasses 17 members: C-X-C motif chemokine ligand 1 (CXCL1) through C-X-C motif chemokine ligand 17 (CXCL17). Among them, C-X-C motif chemokine ligand 8 (CXCL8), which is also known as Interleukin-8 (IL-8), and C-X-C motif chemokine ligand 12 (CXCL12), known as stromal cell-derived factor 1 (SDF-1), are noteworthy [ 45 , 47 , 48 , 50 ]. These chemokines play a pivotal role in recruiting neutrophils and T cells to the site of infection or injury. Accordingly, chemokines are critically important in mediating inflammatory responses and regulating immune functions [ 42 , 46 , 50 ].

In the immune system, CXC chemokines perform essential functions through interactions with receptors ranging from CXCR1 to CXCR8 [ 42 , 48 ]. For instance, CXC chemokines and their receptors are significantly involved in several disease states, including ulcerative colitis, Crohn’s disease, and psoriasis [ 46 ]. CXCL9 and CXCL10 interact with the CXCR3 receptor, which can regulate gene expression in hepatic stellate cells and, accordingly, suppress both fibrosis-related genes and collagen expressions, thereby exerting an anti-fibrotic effect. On the other hand, the CXCL12/CXCR4 axis is suggested to be another potential therapeutic target for mitigating inflammation and fibrosis [ 50 ]. Additionally, During the development of obesity-related diseases, chemokines such as CXCL5 and CXCL8, secreted by white adipose tissue, are highly expressed in the adipose tissue of obese subjects. These factors not only diminish insulin responsiveness in muscle but also exacerbate insulin resistance [ 51 ]. These findings highlight CXC chemokines’ functions in modulating inflammation and immune responses across multiple disease states.

3.1.1. CXCL8

CXCL8, also known as IL-8, binds to the receptors CXCR1 and CXCR2. It is produced by a variety types of cells including Tumor-Associated Macrophages (TAM), adipocytes, fibroblasts, monocytes, epithelial cells, and endothelial cells. CXCL8 is a peptide composed of 72 amino acid residues with a structure consisting of three antiparallel β-folds and an α-helix, stabilized by disulfide and hydrogen bonds, exists in reversible monomeric and dimeric forms, and binds with high affinity to CXCR1 and CXCR2, reinforced by ELR motifs [ 52 , 53 , 54 , 55 , 56 , 57 ]. CXCL8 is a key chemical mediator that is essential for the initiation and activation of neutrophils, especially during the immune system’s response to infection and tissue damage in the human body. CXCL8 regulates leukocyte chemotaxis and activation by interacting with human CXC-type chemokine receptors CXCR1 and CXCR2 [ 54 , 57 ]. CXCL8 plays a key role in tumor progression, such as promoting tumor cells proliferation, invasion, and transformation. It has also been implicated in tumor immune escape mechanisms. CXCL8 has the potential to serve as a prognostic biomarker and therapeutic target [ 56 , 58 ].

Moreover, CXCL8 contributes to atherosclerosis pathogenesis through multiple mechanisms, including attracting immune cells to the lesion site, promoting the migration of vascular cells, and contributing to plaque instability [ 52 ]. Emerging research indicates that CXCL8 is critical in obesity pathophysiology, driving hepatic inflammation and damage through the chemotaxis of neutrophils and macrophages to the liver [ 59 ]. Earlier studies have demonstrated that neutrophils secrete more CXCL8 after being activated by lipopolysaccharide (LPS) and N-Formyl-Met-Leu-Phe (fMLP), highlighting a potential link to the inflammatory response associated with obesity [ 60 ]. Whole-genome transcriptome sequencing has identified the CXCL8 gene as playing a role in both individuals with obesity and those with metabolic impairments. This suggests that CXCL8 may serve as an early biomarker for metabolic risk in these populations [ 61 ].

3.1.2. CXCL9

CXCL9, also known as Monokine induced by Interferon-γ (MIG), is a low molecular weight protein secreted by cells in response to interferon-γ stimulation and is produced mainly by macrophages and endothelial cells. It activates the receptor CXCR3 through its N-terminal interaction with the N-terminal and extracellular structural domains of the receptor. In this way, chemokine CXCL9 directs the migration of immune cells toward sites of inflammation [ 62 , 63 , 64 , 65 ]. CXCL9 induces chemotaxis and participates in immune and inflammatory processes by directing T cells and Natural Killer cells (NK) to migrate to sites of inflammation. CXCL9 plays an important role in tumor immunosurveillance and antitumor immunity [ 63 , 64 , 65 , 66 ].

3.1.3. CXCL10

CXCL10, also known as interferon-Gamma-Induced Protein 10 (IP-10) with a molecular weight of approximately 10 kDa. It is secreted by various cell types, including monocytes, endothelial cells, dendritic cells, neutrophils, and astrocytes. This chemokine is characterized by the presence of the CXC motif, where the first two highly conserved cysteine residues are separated by a single non-cysteine amino acid [ 67 , 68 , 69 ]. CXCL10 binds specifically to its receptor, CXCR3, which is a G-protein-coupled receptor with seven transmembrane domains. After that, CXCL10 can induce the migration of T cells, eosinophils, monocytes, and NK cells toward sites of inflammation, playing a crucial role in both autoimmunity and inflammatory responses [ 67 ]. CXCL10 is expressed in islet cells of type 1 diabetic patients but not in the pancreas of healthy subjects. Similarly, in a mouse model of type 1 diabetes, the levels of CXCL10 increase as the disease progresses [ 68 ]. In patients with obesity, elevated circulating levels of the CXCL10 chemokine have been observed. These levels correlate with markers of obesity such as BMI, waist circumference, and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR). Elevated CXCL10 may enhance leukocyte adhesion to endothelial cells, contributing to abnormal endothelial function. This process is potentially involved in the development of insulin resistance and obesity-related cardiovascular complications [ 70 ]. In addition, CXCL10 gene expression in adipose tissue from obese individuals was found to be significantly correlated with several inflammatory markers, including Interleukin-1 beta (IL-1β), Interleukin-2 (IL-2), IL-6, and CCL2, suggesting that CXCL10 could serve as a potential inflammatory biomarkers [ 71 ].

3.1.4. CXCL14

CXCL14, also known as Breast- and Kidney-Expressed Chemokine (BRAK), is mainly expressed in healthy epithelial tissues such as epithelial cells, adipose tissues, intestines, mast cells, and kidneys, and is also detected in tumor cells, fibroblasts, and macrophages. CXCL14, with a molecular weight of approximately 8–12 kDa, contains four cysteine residues forming two disulfide bonds. The main receptors for CXCL14 remain to be conclusively identified [ 72 , 73 , 74 ]. CXCL14 has a variety of functions, including tumor suppression, antimicrobial, anti-inflammatory, and cell migration regulation [ 72 ]. In obese patients, especially those with type 2 diabetes mellitus, CXCL14 levels usually show a decrease in blood circulation and subcutaneous adipose tissue; In addition, there was an inverse correlation between its level and the expression of inflammation-related genes, whereas a positive correlation was observed with insulin sensitivity markers such as Glucose Transporter Type 4 (GLUT4) and lipocalin. These findings imply that downregulation of CXCL14 may serve as a potential biomarker for obesity-related metabolic dysfunction [ 75 ].

3.2. CC Chemokines

CC chemokines are another important class of chemotactic cytokines that are necessary in regulating the chemotaxis and activation of immune cells. CC chemokines are characterized by two adjacent cysteine residues near the amino terminus. These factors are secreted by different types of cells, including lymphocytes, eosinophils, neutrophils, and monocytes. CC chemokines mediate immune cell chemotaxis and activation by interacting with G protein-coupled receptors on target cells. Activation of these receptors triggers a series of changes via G proteins that activate downstream signaling pathways, such as the phosphatidylinositol signaling pathway, triggering changes in calcium flux and activating protein kinase C [ 45 , 46 , 50 , 76 , 77 ]. The CC chemokine subfamily includes numerous ligands, such as C-C motif chemokine ligand 1 (CCL1) to C-C motif chemokine ligand 28 (CCL28), and each one possesses unique receptor affinities and biological activities [ 45 , 47 , 50 , 76 ].

CC chemokines have complex effects in tumors, not only promoting tumor cell proliferation, migration, and invasion, but also recruiting associated cells to participate in immune and inflammatory responses. These factors can express dual functions by regulating anti-apoptosis and drug resistance in cancer cells, which may be both pro- and anti-cancer [ 76 , 77 ]. CC chemokines also attract and activate immune cells such as macrophages, lymphocytes and neutrophils [ 78 ]. Ligands for CC chemokines such as CCL2, CCL7, CCL8, CCL11, CCL13 to CCL17, CCL22 to CCL24, and CCL26 can bind to receptors from CCR1 to CCR10 [ 45 , 46 , 47 , 76 , 77 ].

CC chemokines bind to receptors from CCR1 to CCR9 and promote immune cell activation, proliferation, differentiation, and migration to sites of inflammation, thus playing a central role in the regulation of immune responses [ 42 ]. The binding of CCL2 to CCR2, especially, activates monocytes, T cells, and basophils, reinforcing their chemotactic and functional activities [ 45 , 47 ]. In addition, CC chemokines interact with G protein-coupled receptors to regulate the migration and activation of leukocytes towards the site of inflammation and modulate the inflammatory response [ 46 ]. Altered CC chemokine expression in adipose tissue of patients with obesity may contribute to insulin resistance and diabetes mellitus, suggesting that interventions targeting CC chemokines provide preventive and therapeutic strategies for type 2 diabetes [ 79 ]. An in-depth understanding of the mechanism of action of CC chemokines in obesity and its associated complications opens up the possibility of developing new therapeutic strategies.

3.2.1. CCL2

CCL2, also known as MCP-1, is a chemokine produced by a variety of cells including tumor cells, monocytes, macrophages, endothelial cells and other inflammatory cells. This mature monomeric chemokine consists of 76 amino acids and forms a stable tertiary structure through two disulfide bonds. The specific binding of CCL2 to the receptor CCR2 promotes the directed movement of immune cells and is essential for the maintenance of immune surveillance. During tissue injury or infection, CCL2 expression is upregulated to recruit monocytes and other immune cells to sites of inflammation [ 80 , 81 , 82 , 83 , 84 , 85 ]. CCL2 also regulates the function of various myeloid cells. It has a major impact on a variety of refractory diseases, including various types of cancer, atherosclerosis, multiple sclerosis and metabolic diseases [ 81 , 83 ]. Further studies of CCL2 are essential to elucidate its mechanism of action and physiological significance.

CCL2, as a key immunomodulatory molecule, promotes the migration of immune cells to adipose tissue and has a significant impact on the inflammatory process associated with obesity [ 10 , 86 ]. In the inflammatory response, CCL2 attracts immune cells to adipose and injured tissues, and leads to macrophage infiltration. Furthermore, CCL2 level has been found to decrease with weight loss [ 10 ]. The pathway of elevated CCL2 gene expression associated with obesity specifically involves Interferon-gamma (IFN-γ) pretreatment. This treatment leads to acetylation of lysine 27 on histone 3 (H3K27), which amplifies LPS-induced CCL2 expression in monocytes [ 87 ]. CCL2 induces inflammation and monocyte recruitment in adipose tissue via its receptor CCR2, which is associated with the exacerbation of metabolic diseases such as atherosclerosis [ 47 ]. Previous research has demonstrated that, although CCL2 knockdown via specific genetic or pharmacological approaches does not prevent macrophage infiltration, the absence of CCL2 exacerbates metabolic dysfunctions, such as impaired insulin sensitivity or glucose homeostasis [ 13 ].

Furthermore, knocking out the G protein-coupled receptor 21 gene (GPR21) decreased monocyte chemotaxis toward CCL2. This was accompanied by a reduction in CCL2 expression and attenuation of downstream signaling. Consequently, inhibiting GPR21 activity may offer a compelling approach to mitigate obesity-induced insulin resistance and CCR2-mediated inflammatory responses [ 88 ]. CCR2 antagonists have potential clinical use in the treatment of inflammatory diseases, pain, and metabolic and cardiovascular diseases [ 80 ]. In mice subjected to a high-fat diet, elevated CCL2 levels in skeletal muscle are associated with an increase in inflammatory cell infiltration, and enhanced binding to the CCR2 receptor is observed after a high-fat intake [ 89 ].

3.2.2. CCL3

CCL3, also known as Macrophage Inflammatory Protein-1 alpha (MIP-1α), is a cytokine belonging to the CC chemokine family. CCL3 is produced by macrophages, B cells, tumor cells, and dendritic cells. The receptors for CCL3 are CCR1 and CCR5 [ 14 , 90 , 91 , 92 , 93 ]. CCL3 interacts with CCR5 and can promote the movement and infiltration of colorectal adenocarcinoma cells. This phenomenon suggests that CCL3 affects colorectal cancer’s progression and metastasis through cancer cell motility [ 91 ]. Additionally, CCL3 can enhance the migration of human neutrophils, and this effect is particularly broad in neutrophils pretreated with Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF). The enhanced migration is important for recruiting neutrophils to inflammation sites. These findings highlight the crucial role of CCL3 in inflammatory responses and immune regulation [ 90 ]. In the obese state, the expression of CCL3 is elevated in both circulating blood and adipose tissues, playing a significant role in the development of Non-alcoholic fatty liver disease (NAFLD), which is induced by diets high in cholesterol and fat [ 14 , 94 ]. Furthermore, the inhibition of CCL3 has been shown to mitigate liver inflammation, and to improve hepatic insulin resistance and steatosis [ 14 ]. This suggests that targeting CCL3 could be a potential therapeutic strategy for managing NAFLD and its associated metabolic disturbances.

3.2.3. CCL5

CCL5, also known as regulated upon activation, normal T cell expressed and secreted (RANTES), is a chemokine predominantly produced by NK cells, T cells, dendritic cells, and macrophages/monocytes. This chemokine interacts with multiple receptors, notably CCR1, CCR3, and CCR5, to recruit and activate immune cells during inflammatory and immune responses. The broad range of cell types capable of producing CCL5, along with its interaction with diverse receptors, underscores its significance in mediating immune and inflammatory responses [ 16 , 95 , 96 , 97 ]. CCL5 participates in anti-tumor activity and physiological processes such as cell migration and immune response [ 16 , 96 ]. In the obese state, adipose tissue enhances signaling from CCL5 and its receptor CCR5 to suppress inhibition of AMP-activated protein kinase (AMPK), which decreases lipolysis and oxidative metabolism. This ultimately results in a reduction of energy expenditure and adaptive thermogenesis, further exacerbating the development of obesity and insulin resistance [ 17 ]. The expression levels of CCR5 and CCL5 were found to be significantly elevated in adipose tissue during inflammation and insulin resistance associated with obesity. This upregulation plays a crucial role in the recruitment and polarization of adipose tissue macrophages (ATMs), which are pivotal in the development of insulin resistance. Specifically, genetic deletion of CCR5 in a mouse model leads to a reduction in the number of ATMs and shifts ATMs towards the M2 phenotype. These findings underscore the importance of CCR5 in modulating adipose tissue inflammation and suggest its potential as a therapeutic target for ameliorating insulin resistance in obesity [ 98 ]. Multiple studies have shown that CCL5 enhances insulin signaling in the hypothalamus through the CCR5 receptor, thereby increasing systemic insulin responsiveness [ 97 ].

3.2.4. CCL7

CCL7, also known as Monocyte Chemoattractant Protein-3 (MCP-3), is a single-chain polypeptide consisting of 99 amino acids, including a 23-amino-acid signal peptide and a 76-amino-acid mature form. It is produced by tumor cells, fibroblasts, endothelial cells, vascular smooth muscle cells, and bone marrow mononuclear cells. CCL7 binds to receptors such as CCR1, CCR2, CCR3, and CCR5 [ 99 , 100 , 101 ]. As a chemoattractant, CCL7 facilitates the migration and accumulation of monocytes and macrophages through its specific receptors and plays a role in various physiological processes, including cell migration, immune response, inflammation, and tumor development [ 99 , 100 ]. CCL7 has a strong affinity for its primary receptor, CCR2 that mediates the pathophysiological mechanisms in monocytes and macrophages. CCL7 effectively recruits leukocytes to sites of inflammation through receptor binding [ 101 ]. In murine models of diet-induced obesity and hepatic steatosis, overexpression of CCL7 confers protection against these conditions [ 102 ]. A significant role of CCL7 and adiposity has been identified in facilitating the migration and infiltration of inflammatory cells [ 103 ]. In the context of obesity and distal sensorimotor polyneuropathy (DSPN), CCL7 serves as a potential inflammatory biomarker, reflecting its correlation with BMI and waist circumference, and appearing to partially mediate the relationship between obesity and DSPN [ 104 ].

3.3. XC

XC is a member of the C family of chemokines, with its sole ligand being C motif chemokine ligand 1 (XCL1), also known as lymphotactin. This small protein is primarily secreted by activated immune cells, including CD8 + T cells, NK cells, mast cells, and Th1-polarized CD4 + T cells [ 105 , 106 , 107 , 108 , 109 ]. XCL1 is recognized for its unique ability to bind to the 7-transmembrane G-protein-coupled receptor XCR1. It is distinguished as the only chemokine that forms a disulphide bond, featuring a metastable folding structure. This enables XCL1 to alternate between conventional chemokine folds and unique β-folded dimers [ 108 , 110 , 111 , 112 ]. Although the XC chemokine family has fewer members, its role in immunomodulation cannot be ignored.

XCL1 interacts with XCR1 to recruit activated T cells and NK cells [ 108 ]. Inhibiting the XCL1-XCR1 interaction may offer therapeutic benefits in treating various inflammatory conditions. However, enhancing this signaling pathway also improves responses to severe infections and cancer treatments [ 111 ]. Moreover, XCL1 contributes to bactericidal activities and the immune response [ 110 ]. The specific role and systemic regulation of XCL1 in obesity is not fully understood; however, its specific expression in regions of fat deposition suggests a complex link to obesity [ 112 ]. Studies of XC chemokines have uncovered new roles for them in obesity and immune responses, providing new perspectives for future therapies.

4. Role of Chemokines in Obesity

Obesity is associated with a chronic inflammatory state in which chemokines play an important role, influencing the recruitment and activation of immune cells. Chemokines and their receptors direct circulating leukocytes to the site of inflammation and injury [ 47 ]. For example, the CC and CXC chemokine families are primarily responsible for attracting monocytes and polymorphonuclear leukocytes to sites of chronic and acute inflammation, respectively. In addition, these chemokines are involved in the regulation of adaptive immune responses and play a key role in the pathogenesis of several diseases [ 42 , 45 , 46 , 47 ].

4.1. CC Critical Role of Chemokines in Obesity-Related Inflammation

In the state of obesity, adipose tissue releases various chemokines and inflammatory factors, including MCP-1, TNF-α, IL-1β, and IL-6. These factors can activate signaling pathways such as Nuclear Factor kappa B (NF-κB) and c-Jun N-terminal Kinase (JNK), and may lead to inflammatory responses. Concurrently, obesity may also change adipocyte size and number to impact chemokine and inflammatory factor expression and release [ 113 ]. Examples include the association between MCP-1 and RANTES and obesity [ 49 , 114 ].

This is accompanied by the release of a large number of chemokines. These chemokines not only affect diseases related to the immune system, but may also have potential significance in the treatment of obesity [ 49 ]. Chemokines CCL2 and CCL5 have been associated with elevated levels in adipose tissue in obesity [ 114 ]. Elevation of CCL2 in the adipose tissue of patients with obesity attracts monocytes, resulting in inflammation and insulin resistance within the adipose tissue. Conversely, CCL2 levels decline accompanied by weight loss. Additionally, CCL2’s interaction with proteoglycans promotes tissue inflammation and fibrosis [ 10 ]. The increased expression of free fatty acids in circulation may serve as a trigger for the upregulation of these chemokines through the inhibitor of κB kinase β (IKKβ) and JNK pathways. The resultant overproduction of inflammatory cytokines and chemokines further exacerbates the inflammatory response associated with obesity [ 11 , 115 ]. In terms of disease prevention, weight loss has been shown to reduce serum concentrations of the chemokine MCP-1 in obese men with metabolic syndrome and to improve markers associated with renal injury, suggesting that renal tubular injury can be ameliorated by reducing inflammation [ 116 ]. In addition, chemokines may also serve as a potential biomarker for predicting childhood obesity and insulin resistance [ 117 ].

During obesity, the expression and activity of inflammatory factors are altered, including the up-regulation of CCL2, which leads to more macrophages being recruited into adipose tissue and exacerbate metabolic inflammation [ 10 , 118 ]. Chemokines and inflammatory mediators are key regulators of the inflammatory responses and pathophysiological processes in obesity-related conditions [ 119 ]. In obesity, adipocytes secrete more adipokines that recruit and activate macrophages, and intensify inflammation within adipose tissue. While activated macrophages in adipose tissue secrete additional mediators to recruit more macrophages and perpetuate a positive feedback loop that sustains adipose tissue inflammation, this persistent inflammation contributes to the development of insulin resistance [ 120 ]. In a mouse model of diet-induced obesity and hepatic steatosis, overexpression of CCL7 protects the organism from these diseases [ 102 ]. Further studies have found that CCL7 and adiposity play an important role in promoting migration and infiltration of inflammatory cells [ 103 ]. In terms of obesity and DSPN, CCL7 is a potential biomarker of inflammation, reflecting its correlation with BMI and waist circumference. CCL7 may partially mediate the relationship between obesity and DSPN [ 104 ]. Therefore, the key role of CC chemokines in obesity-associated inflammation and metabolic disorders emphasizes their importance as potential targets for the treatment of obesity and related complications.

4.2. CXC Chemokines Modulate Obesity Inflammation and Metabolism

CXC chemokines regulate inflammation associated with obesity, impact immune cell infiltration, tumor progression, and insulin resistance. Specific factors such as CXCL16/CXCR6, CXCL9/10/11, and CXCL12/CXCR4 are implicated in cellular recruitment. The inhibition of these chemokines demonstrates therapeutic promise, yet further research is required to elucidate their molecular pathways [ 51 ]. Studies have demonstrated that adipocytes secrete the CXCL12 chemokine, which attracts macrophages into adipose tissue, inducing inflammatory responses and impairing insulin sensitivity. In murine models of obesity, both the expression and secretion of CXCL12 are elevated. Inhibiting the CXCL12 signaling pathway has been shown to effectively decrease macrophage accumulation in adipose tissue and aid in restoring insulin sensitivity. These findings reveal a potential regulatory role for CXCL12 in obesity-related metabolic disorders [ 121 ]. Another chemokine, CXCL14 regulates energy metabolism. CXCL14 counteracts metabolic disorders and insulin resistance associated with obesity by stimulating brown adipose tissue activity, promoting browning of white adipose tissue, and recruiting M2-type macrophages [ 122 ]. A related study found that overexpression of CXCL1 in muscle attenuates fat accumulation induced by a high-fat diet, and enhances the muscle’s ability to oxidize fatty acids. This suggests the capacity of CXCL1 to prevent and treat obesity [ 123 ]. The regulatory role of CXC chemokines offers new strategies for obesity treatment, particularly in reducing inflammation and improving metabolic health.

5. Effect of Chemokine Knockout or Pharmacological Inhibition on Obesity

5.1. Effects and Mechanisms of Pharmacological Inhibition of Chemokines on Obesity

5.1.1. Analysis of the Role and Effects of CXC Inhibitors in the Regulation of Inflammation and Metabolism in Obesity

Pharmacological inhibition of chemokines offers a novel approach to obesity treatment by modulating inflammatory state and metabolic pathways. Chemokine inhibitors have been studied and have been demonstrated to play an important role in the obesity process. Cui et al. [ 18 ] administered a CXCL8 analogue, CXCL8 (3–72) K11R/G31P (briefly named G31P), an inhibitor of CXCR1 and CXCR2, to db/db mice to evaluate its protective effects against immunometabolic disorders. The treatment significantly improved glycemic control, insulin sensitivity, and lipid metabolism by modulating the inflammatory response. G31P effectively reduced the infiltration of inflammatory cells and circulating cytokine levels in the liver and adipose tissues. Meanwhile, this treatment promoted the activation of anti-inflammatory M2 macrophages and attenuated obesity-induced inflammation. While CXC chemokine inhibitors such as G31P show a prospective power in regulating obesity-related metabolism. However, current research on CXC inhibitors leaves much to be desired.

5.1.2. Effects of CC Inhibitors and Other Pharmacologic Interventions on Obesity and Metabolic Disorders

In addition to other antagonists, specific CCR2 antagonists have shown efficacy in reducing blood glucose and enhancing insulin sensitivity in obesity treatments. They also contribute to the attenuation of lipid accumulation and inflammation in both liver and adipose tissue. These antagonists regulate lipid metabolism by diminishing macrophage accumulation in adipose tissues. However, they have different effects in lipid levels. Some antagonists may reduce triglycerides, but they do not change total cholesterol consistently [ 124 ].

In addition, propagermanium, a chemokine receptor CCR2 antagonist, has demonstrated efficacy in mitigating metabolic disorders associated with a high-fat diet-induced obesity mouse model. It attenuates weight gain and visceral fat accumulation, decreases the aggregation of pro-inflammatory M1-type macrophages, and promotes polarization towards anti-inflammatory M2-type macrophages in adipose tissue. Propagermanium also enhances insulin sensitivity and modulates levels of lipocalin and leptin, as well as augments lipoxygenase activity in hepatic and muscle tissues. It reduces hepatic triglyceride levels and curbs inflammation. Furthermore, propagermanium seems to decrease leptin resistance in adipose tissue. All of this suggests its role in impeding obesity through multifaceted pathways [ 125 ].

Tamura et al. [ 126 ] investigated the effects of propagermanium (a CCR2 inhibitor) on obesity and type 2 diabetes by administering a standard diet supplemented with propagermanium to 6-week-old db/db mice for 12 weeks. The treatment with propagermanium significantly mitigated weight gain, visceral fat accumulation, and adipocyte hypertrophy. It also reduced macrophage infiltration and inflammatory responses in adipose tissue. Moreover, it enhanced glucose tolerance, insulin sensitivity, and decreased triacylglycerol levels in the liver. This was accompanied by a reduction in hepatic fat synthesis, TNF-α expression, and monocyte migration. These findings indicate that targeting adipose tissue inflammation via CCR2 inhibition can potentially alleviate obesity and its associated metabolic disturbances.

Cenicriviroc (CVC) is an orally administered dual inhibitor of the C-C chemokine receptors CCR2 and CCR5. It effectively hampers monocyte infiltration in the liver by curtailing the heightened expression of these chemokines in hepatic injury. Consequently, CVC administration leads to a reduction in serum cholesterol and triacylglycerol levels in mice with steatohepatitis. This results in less weight gain and fat accumulation in the liver. Furthermore, it ameliorates insulin resistance and lowers hepatic triglyceride content [ 127 ].

The administration of a neutralizing monoclonal antibody against CCL4 enhanced glucose metabolism and lipid profiles, altered the composition and functionality of the intestinal microbiota, mitigated inflammation, and aided in controlling insulin resistance and the progression of hyperglycemic symptoms in a mouse model of diet-induced diabetes [ 128 ]. Pharmacological inhibition of bile salt hydrolase (BSH) not only decelerates the advancement of obesity-associated colon cancer in a high-fat diet model but also exhibits antitumor effects by disrupting the β-catenin/CCL28 signaling pathway [ 129 ].

5.2. Effects and Mechanisms of Knockdown of Chemokines on Obesity

5.2.1. Dual Effects of CXC Knockout on Obesity

Obese adipose tissue secretes chemokines that may have detrimental effects on the organism. Mice with MCP-1 gene knockouts showed reduced adipogenesis and less adipocyte hypertrophy when fed a high-fat diet compared to wild-type mice . These knockout mice also exhibited enhanced insulin sensitivity, decreased insulin secretion, reduced blood levels of inflammatory and angiogenic factors, and diminished incidence and growth of mammary tumors [ 130 ]. Conversely, some gene knockouts resulted in opposite effects. CXCR4 possesses multiple roles in adipocytes. Firstly, it regulates the infiltration of inflammatory cells into adipose tissue, thus diminishing obesity-associated inflammation. Secondly, CXCR4 is involved in the thermogenic response of brown adipose tissue to augment energy dissipation, which results in a decline in fat deposits and obesity. However, knockout of CXCLR4 may aggravate obesity and damage the thermogenic capacity of brown adipose tissue, along with an increase in inflammatory cells within white adipose tissue. Moreover, CXCR4 interacts with its ligand CXCL12, influencing cell migration and localization. CXCR4 is pivotal for embryonic development, as well as for the homeostasis and functioning of the immune and stem cell systems [ 131 ].

5.2.2. Effects of CC Knockout on Obesity and Metabolic Disorders

Duffy antigen receptor for chemokines (DARC) is a multifunctional nonsignaling receptor and expresses on red blood cells and other cell types. It regulates inflammation and cell migration by binding to chemokines such as MCP-1. The absence of the DARC gene is associated with exacerbated insulin resistance and adipose tissue inflammation under a high-fat diet. Experiments have demonstrated that mice lacking the DARC gene exhibit an increase in body weight, reduced glucose tolerance, decreased insulin sensitivity, and enhanced inflammatory markers in adipose tissue [ 132 ].

Zhou et al. [ 133 ] reported that knocking out CCL5 in normal weight mice improved glucose tolerance and pancreatic islet function, whereas a knockout of CCL5 in obese mice exacerbates insulin resistance and hepatic fat accumulation. Additionally, this knockout may increase the expression of other chemokines to enhance immune responses. These findings illustrate the multifaceted effects of CCL5 knockout on metabolism in mice , but these effects may depend on the animal’s weight status. However, Chan et al. [ 16 ] demonstrated that mice deficient in CCL5 gained less weight and exhibited lower levels of blood glucose and insulin, as well as improved insulin sensitivity, when fed a high-fat diet compared to their wild-type counterparts, and these effects occurred independently of food intake. The absence of CCL5 also led to reduced lipid accumulation and inflammation in adipose tissue, facilitated a shift in macrophage polarization from the M1 to the M2 phenotype, and modulated the levels of pro-inflammatory and anti-inflammatory cytokines. Furthermore, CCL5 influenced the composition of immune cell populations within the adipose tissue, potentially contributing to a decreased risk of developing obesity-associated insulin resistance.

CCR2 is a chemokine receptor that is closely associated with obesity-induced kidney injury and its associated oxidative stress and endoplasmic reticulum stress. Knockdown of CCR2, even in the context of obesity, can attenuate renal injury, prevent excessive immune cell infiltration, and reduce inflammation and fibrosis, thus improving renal function [ 134 ]. Although pharmacological inhibition and knockout chemokines show potential in obesity treatment, further studies are needed to determine their long-term effects and safety, Figure 2 .

6. The Effect of Exercise on Weight Management and the Role of Chemokines in This Process

6.1. Effectiveness of Exercise for Weight Management

With obesity increasing globally, exercise as an effective weight management method becomes more important. The main cause of obesity is an imbalance between energy intake and expenditure [ 135 ]. Fortunately, exercise can improve this imbalance, which means engaging in aerobic, resistance, and combined exercise to promote energy expenditure and weight loss.

6.1.1. Aerobic Exercise

Aerobic workouts rely on oxygen for energy, which helps to boost cardiorespiratory fitness, cardiovascular health, improve metabolism, and promote weight loss. Types of aerobic exercise include walking, brisk walking, light jogging, and cycling [ 136 , 137 ]. Aerobic exercise optimizes adipose metabolism by increasing subcutaneous fat utilization, improving response to insulin, promoting mitochondrial activity, reducing inflammation and adipose tissue browning [ 138 ]. Single bouts of aerobic exercise are associated with an increase in M2-type macrophages and neutrophils in skeletal muscle, which corresponds to improved insulin sensitivity under obese conditions [ 139 ]. Long-term aerobic training modulates adipokine secretion, protects muscle mitochondria from high-fat dietary injury, improves metabolic efficiency, reduces visceral fat and improves waist circumference [ 140 , 141 , 142 ]. For example, 12 weeks of aerobic exercise reduced body weight, decreased hepatic fat and inflammation, inhibited the TLR4 signaling pathway, and enhanced the activity of ApoA5 in mice , effectively ameliorating NASH induced by a high-fat diet [ 31 ]. Furthermore, studies confirmed that both HIIT and MICT are effective in increasing energy expenditure and contributing to weight loss [ 143 ].

6.1.2. Resistance Movements

Resistance training imposes incremental loads to the body by self-body weight or exercise equipment to enhance muscle strength and size. This training not only promotes muscle development, but also contributes to cardiovascular fitness, prevents osteoporosis, and manages body weight [ 136 , 144 , 145 , 146 ]. In animal models, resistance training has been shown to improve insulin resistance and glucose tolerance, reduce adipocyte size, and activate insulin pathways in skeletal muscle [ 147 ]. In addition, resistance training reduces visceral fat, body weight, adiposity, and blood pressure while improving fat-free muscle mass and strength, decreasing body fat percentage and enhancing muscle-related fitness [ 148 , 149 , 150 , 151 ]. Resistance exercise also combats obesity and its complications by enhancing insulin signaling, reducing inflammatory responses, promoting favorable adjustments within the NADPH oxidase system, and improving the efficiency of insulin-mediated glucose clearance [ 152 , 153 ].

6.1.3. Integrated Movement Forms

Interdisciplinary treatment combining aerobic exercise and resistance training is particularly effective in adolescent obesity. This exercise has demonstrated its benefits in reducing body fat and visceral fat, lowering low-density lipoprotein (LDL), and cholesterol [ 154 ]. Integrated exercise not only improves the endurance of the cardiovascular system, but also enhances muscle mobility, effectively reduces fat deposition, and improves glycemic control with reduced insulin resistance [ 155 ]. Compared to resistance exercise alone, combined exercise is more effective in preventing and controlling obesity, especially in populations with a higher body fat percentage [ 156 ]. Elderly obese individuals can maximize fitness and oxygen consumption with this combined exercise, which facilitates improvement in body weight and lean body mass [ 157 ]. Compared with resistance training alone, integrated exercise substantially increases maximal oxygen consumption and enhanced muscle strength in individuals with obesity by combining aerobic and resistance exercise [ 158 ]. Integrated exercise also helps to reduce body fat content, BMI, and adiposity in children with obesity, while increasing lean BMI significantly reducing cardiovascular risk and obesity-related inflammation [ 159 ]. It has been shown that combined exercise during dietary weight loss significantly slows the decline in bone mineral density (BMD) in individuals with obesity. All ages and body mass index categories of people with obesity benefit from the protective effects of exercise on bone mineral density [ 160 , 161 , 162 ]. Based on integrated exercise to promote energy expenditure and fat oxidation through multiple mechanisms, it has significant benefits for improving obesity and promoting health. Therefore, it is recommended as the preferred option for weight management to enhance weight loss.

6.2. Role and Mechanisms of Chemokines in Exercise Weight Loss

Exercise as an effective method of weight loss, such as aerobic exercise, not only reduces subcutaneous fat in obese individuals, but also prevents chronic inflammation of skeletal muscle and insulin resistance. Furthermore, exercise modulates the NF-κB signaling pathway to impact body composition positively and ameliorate cardiovascular disease risk factors. During exercise for weight loss, it also causes changes in the levels of chemokines in skeletal muscle, including CCL2, CCL7, and CXCL1. Given age and biorhythm considerations, a new perspective of intervention through physical activity is offered for metabolic disorders [ 139 , 158 , 163 , 164 , 165 ]. In addition, exercise-induced weight loss reduces the volume of white adipose tissue and ameliorates tissue hypoxia, which leads to reduced chemokine expression [ 166 ]. For example, exercise upregulates RANTES levels in the adipose tissue and serum of obese mice , affects the immune system, may lead to weight loss and alter immune status within adipose tissue [ 167 ]. Relatedly, improvements in metabolic biomarkers such as blood pressure and blood glucose tend to coincide with exercise-induced weight loss, which is associated with reductions in visceral adiposity and expression of chemokines such as MCP-1 [ 168 ]. Thus, chemokines play a key role in the obese state by directing and attracting immune cells into adipose tissue [ 169 ].

In the obese state, increased expression of MIP-1α/CCL3 in adipose tissue is positively correlated with elevated levels of TNF-α and CD163 [ 94 ]. In contrast, the infiltration of inflammatory macrophages and CD8 + T cells can be reduced by exercise, which decreases the expression of TNF-α and IL-6 in adipose tissue and slows down adipose-generated inflammation [ 170 ]. Relevant studies have shown that exercise reduces the expression of TNF-α and IL-6 in adipose tissue by decreasing the infiltration of inflammatory macrophages and CD8 + T cells. These cells are involved in adipocyte differentiation and fat metabolism, and thus exercise contributes to fat loss [ 31 ]. Recruitment of hepatic macrophages can be manipulated by knockdown of CCL3, altering the M1/M2 balance and thereby ameliorating steatohepatitis induced by a high-fat diet [ 14 ]. Downregulation of CCL3 also helps to reduce inflammatory cell infiltration in adipose tissue and decreases the expression levels of genes involved in fatty acid synthesis and fatty acid oxidation [ 171 ].

It was shown that ccr7 −/− mice in an obese mouse model were able to counteract high-fat diet-induced weight gain and insulin resistance by increasing calorie consumption and decreasing inflammatory activity. This reveals the regulatory role of the CCL19-CCR7 signaling pathway in the development of obesity and its associated state of insulin resistance [ 172 ]. In the development of obesity pathology, weight loss has been shown to effectively lower CCL2 levels, thereby alleviating inflammation and reducing the risk of related conditions, such as macrophage activation, hepatocellular carcinoma, rheumatoid arthritis, and multiple myeloma [ 10 , 86 ]. Targeted knockdown or pharmacological inhibition of these chemokines, such as the deletion of the CCR2 receptor that binds to the CCL2 ligand, has been shown to ameliorate metabolic abnormalities in obese individuals. This intervention can help to reduce fat accumulation, oxidative stress, and endoplasmic reticulum stress [ 134 ]. similarly, exercise reduces CCL2 secretion that also reduces the inflammatory response associated with obesity [ 173 ]. Further, knockdown of MCP-1 enhances M2 polarization in adipose tissue, promotes the conversion of white to brown fat, and increases the activity of brown adipose tissue [ 174 ].

In obesity-associated immune surveillance, CXC chemokines have a critical impact on insulin resistance and lipid metabolism by recruiting immune cells through binding to receptors and modulating inflammation. Physical activity, as part of an integrated lifestyle, is effective in reducing levels of the chemokine IP10/CXCL10 in the immune system, thus potentially helping to alleviate obesity-related immunometabolic problems [ 51 , 175 ]. Altered gene expression of CXCL10 and CCL2 chemokines in prefrontal cortex was associated with exercise-induced weight loss. Exercise prevents the induction of these chemokines to reduce the inflammatory response associated with obesity. Although exercise has a smaller effect on the expression of inflammation-related genes in the prefrontal cortex, it overall reduces specific functional gene clusters associated with inflammation. This includes the expression of the p65 subunit of NFkB and IKBα [ 173 ]. A study reported a subsequent decrease in serum CXCL5, HOMA-IR, and TNFα levels in sedentary women with obesity after a 12-week exercise training program. These findings indicate that exercise-induced weight loss reduces serum CXCL5 concentrations and improves insulin resistance [ 176 ]. In addition, low-intensity exercise significantly affected the expression of B Lymphocyte Chemoattractant (BLC), eotaxin, Granulocyte Chemotactic Protein 2 (GCP-2), Monocyte Chemoattractant Protein 4 (MCP-4) and Neutrophil Activating Peptide 2 (NAP2) expression. These chemokines play an important role in mediating chemotactic responses [ 177 ]. The mechanisms by which exercise regulates the expression of these chemokines may provide a novel strategy for intervening in obesity, particularly in terms of reducing inflammation and improving metabolic health, Figure 3 .

7. Conclusions

This paper provides insight into how exercise influences the pathogenesis of obesity by regulating chemokine expression. We revealed the remarkable effect of this intervention in reducing pro-inflammatory chemokines such as CCL2, CCL3, CCL5, CCL7, and CXCL8. It also highlights the role of physical activity in regulating complex immune factors like CXCL9, CXCL10, and XCL1, and in enhancing the expression of the protective chemokine CXCL14. These changes improve insulin sensitivity, promote healthful fat metabolism, decrease inflammatory cell infiltration, and enhance metabolic activity in adipose tissue, offering new research directions for the intervention and management of obesity and its complications. Future studies should explore in greater depth the specific mechanisms through which physical activities modulate individual chemokines and assess the optimal effects of different types and intensities of activities, such as aerobic, combined aerobic and resistance exercises, and comparing HIIT to MICT on chemokine expression, in obesity management. Particularly, this study directs attention towards personalized obesity intervention strategies.

Acknowledgments

The authors extend their heartfelt thanks to the entire team for their unwavering commitment and the exceptional professionalism and diligence shown throughout the literature compilation and review process. We also thank Figdraw ( www.figdraw.com , accessed on 20 August 2024) for the assistance in creating the figures.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Author Contributions

W.H.: Writing—review, editing, Visualization, writing—original draft & Methodology. X.L.: methodology, editing, Funding acquisition, writing-review & revision. L.Z.: Writing—review, Funding acquisition & methodology. H.W.: Writing—original draft, Supervision & Review. G.Y.: Writing—review & Supervision. All authors have read and agreed to the published version of the manuscript.

Conflicts of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Lopez-Jimenez F. Almahmeed W. Bays H. Cuevas A. Di Angelantonio E. le Roux C.W. Sattar N. Sun M.C. Wittert G. Pinto F.J. Obesity and cardiovascular disease: Mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation Eur. J. Prev. Cardiol. 2022 29 2218 2237 10.1093/eurjpc/zwac187 36007112

2. Spinelli A. Buoncristiano M. Nardone P. Starc G. Hejgaard T. Júlíusson P.B. Fismen A.S. Weghuber D. Musić Milanović S. García-Solano M. Thinness, overweight, and obesity in 6- to 9-year-old children from 36 countries: The World Health Organization European Childhood Obesity Surveillance Initiative-COSI 2015–2017 Obes. Rev. Off. J. Int. Assoc. Study Obes. 2021 22 (Suppl. S6) e13214 10.1111/obr.13214 34235850

3. Buoncristiano M. Spinelli A. Williams J. Nardone P. Rito A.I. García-Solano M. Grøholt E.K. Gutiérrez-González E. Klepp K.I. Starc G. Childhood overweight and obesity in Europe: Changes from 2007 to 2017 Obes. Rev. Off. J. Int. Assoc. Study Obes. 2021 22 (Suppl. S6) e13226 10.1111/obr.13226 34378305

4. Tham K.W. Abdul Ghani R. Cua S.C. Deerochanawong C. Fojas M. Hocking S. Lee J. Nam T.Q. Pathan F. Saboo B. Obesity in South and Southeast Asia-A new consensus on care and management Obes. Rev. Off. J. Int. Assoc. Study Obes. 2023 24 e13520 10.1111/obr.13520 36453081 PMC10078503

5. Wang L. Zhou B. Zhao Z. Yang L. Zhang M. Jiang Y. Li Y. Zhou M. Wang L. Huang Z. Body-mass index and obesity in urban and rural China: Findings from consecutive nationally representative surveys during 2004-18 Lancet 2021 398 53 63 10.1016/S0140-6736(21)00798-4 34217401 PMC7617101

6. Wang Y.F. Zhao L. Gao L.W. Pan A. Xue H. Obesity in China 3 Health policy and public health implications of obesity in China Lancet Diabetes Endocrinol. 2021 9 446 461 10.1016/S2213-8587(21)00118-2 34097869

7. Lin X. Li H. Obesity: Epidemiology, Pathophysiology, and Therapeutics Front. Endocrinol. 2021 12 706978 10.3389/fendo.2021.706978 PMC8450866 34552557

8. Powell-Wiley T.M. Poirier P. Burke L.E. Després J.P. Gordon-Larsen P. Lavie C.J. Lear S.A. Ndumele C.E. Neeland I.J. Sanders P. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association Circulation 2021 143 e984 e1010 10.1161/CIR.0000000000000973 33882682 PMC8493650

9. Rohm T.V. Meier D.T. Olefsky J.M. Donath M.Y. Inflammation in obesity, diabetes, and related disorders Immunity 2022 55 31 55 10.1016/j.immuni.2021.12.013 35021057 PMC8773457

10. Dommel S. Blüher M. Does C-C Motif Chemokine Ligand 2 (CCL2) Link Obesity to a Pro-Inflammatory State? Int. J. Mol. Sci. 2021 22 1500 10.3390/ijms22031500 33540898 PMC7867366

11. Jiao P. Chen Q. Shah S. Du J. Tao B. Tzameli I. Yan W. Xu H. Obesity-related upregulation of monocyte chemotactic factors in adipocytes: Involvement of nuclear factor-kappaB and c-Jun NH2-terminal kinase pathways Diabetes 2009 58 104 115 10.2337/db07-1344 18835938 PMC2606857

12. Lee D. Kim D.W. Yoon S. Nam A.R. Lee K.H. Nam K.H. Cho S.M. Yoon Y. Cho J.Y. CXCL5 secreted from macrophages during cold exposure mediates white adipose tissue browning J. Lipid Res. 2021 62 100117 10.1016/j.jlr.2021.100117 34537202 PMC8512628

13. Inouye K.E. Shi H. Howard J.K. Daly C.H. Lord G.M. Rollins B.J. Flier J.S. Absence of CC chemokine ligand 2 does not limit obesity-associated infiltration of macrophages into adipose tissue Diabetes 2007 56 2242 2250 10.2337/db07-0425 17473219

14. Xu L. Chen Y. Nagashimada M. Ni Y. Zhuge F. Chen G. Li H. Pan T. Yamashita T. Mukaida N. CC chemokine ligand 3 deficiency ameliorates diet-induced steatohepatitis by regulating liver macrophage recruitment and M1/M2 status in mice Metab. Clin. Exp. 2021 125 154914 10.1016/j.metabol.2021.154914 34656648

15. Luciano-Mateo F. Cabré N. Fernández-Arroyo S. Baiges-Gaya G. Hernández-Aguilera A. Rodríguez-Tomàs E. Mercado-Gómez M. Menendez J.A. Camps J. Joven J. Chemokine (C-C motif) ligand 2 gene ablation protects low-density lipoprotein and paraoxonase-1 double deficient mice from liver injury, oxidative stress and inflammation Biochim. Biophys. Acta Mol. Basis Dis. 2019 1865 1555 1566 10.1016/j.bbadis.2019.03.006 30905786

16. Chan P.C. Lu C.H. Chien H.C. Tian Y.F. Hsieh P.S. Adipose Tissue-Derived CCL5 Enhances Local Pro-Inflammatory Monocytic MDSCs Accumulation and Inflammation via CCR5 Receptor in High-Fat Diet-Fed Mice Int. J. Mol. Sci. 2022 23 4226 10.3390/ijms232214226 36430701 PMC9692513

17. Chan P.C. Hung L.M. Huang J.P. Day Y.J. Yu C.L. Kuo F.C. Lu C.H. Tian Y.F. Hsieh P.S. Augmented CCL5/CCR5 signaling in brown adipose tissue inhibits adaptive thermogenesis and worsens insulin resistance in obesity Clin. Sci. 2022 136 121 137 10.1042/CS20210959 34821367

18. Cui S. Qiao L. Yu S. Men L. Li Y. Li F. Du J. The antagonist of CXCR1 and CXCR2 protects db/db mice from metabolic diseases through modulating inflammation Am. J. Physiol. Endocrinol. Metab. 2019 317 E1205 E1217 10.1152/ajpendo.00117.2019 31573846

19. Yoon Y.S. Liu W. Van de Velde S. Matsumura S. Wiater E. Huang L. Montminy M. Activation of the adipocyte CREB/CRTC pathway in obesity Commun. Biol. 2021 4 1214 10.1038/s42003-021-02735-5 34686752 PMC8536733

20. Yan L. DeMars L.C. Johnson L.K. Long-term voluntary running improves diet-induced adiposity in young adult mice Nutr. Res. 2012 32 458 465 10.1016/j.nutres.2012.05.006 22749182

21. Leggate M. Carter W.G. Evans M.J. Vennard R.A. Sribala-Sundaram S. Nimmo M.A. Determination of inflammatory and prominent proteomic changes in plasma and adipose tissue after high-intensity intermittent training in overweight and obese males J. Appl. Physiol. (Bethesda Md. 1985) 2012 112 1353 1360 10.1152/japplphysiol.01080.2011 22267387 PMC3331586

22. Barry J.C. Simtchouk S. Durrer C. Jung M.E. Little J.P. Short-Term Exercise Training Alters Leukocyte Chemokine Receptors in Obese Adults Med. Sci. Sports Exerc. 2017 49 1631 1640 10.1249/MSS.0000000000001261 28319586

23. Xia W.H. Li J. Su C. Yang Z. Chen L. Wu F. Zhang Y.Y. Yu B.B. Qiu Y.X. Wang S.M. Physical exercise attenuates age-associated reduction in endothelium-reparative capacity of endothelial progenitor cells by increasing CXCR4/ JAK-2 signaling in healthy men Aging Cell 2012 11 111 119 10.1111/j.1474-9726.2011.00758.x 22018014

24. Steppich B. Dayyani F. Gruber R. Lorenz R. Mack M. Ziegler-Heitbrock H.W. Selective mobilization of CD14(+)CD16(+) monocytes by exercise Am. J. Physiol. Cell Physiol. 2000 279 C578 C586 10.1152/ajpcell.2000.279.3.C578 10942707

25. Okutsu M. Suzuki K. Ishijima T. Peake J. Higuchi M. The effects of acute exercise-induced cortisol on CCR2 expression on human monocytes Brain Behav. Immun. 2008 22 1066 1071 10.1016/j.bbi.2008.03.006 18477503

26. Fernández-Verdejo R. Vanwynsberghe A.M. Essaghir A. Demoulin J.B. Hai T. Deldicque L. Francaux M. Activating transcription factor 3 attenuates chemokine and cytokine expression in mouse skeletal muscle after exercise and facilitates molecular adaptation to endurance training FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2017 31 840 851 10.1096/fj.201600987R 27856557

27. Sarma S. Sockalingam S. Dash S. Obesity as a multisystem disease: Trends in obesity rates and obesity-related complications Diabetes Obes. Metab. 2021 23 (Suppl. S1) 3 16 10.1111/dom.14290 33621415

28. Heindel J.J. Howard S. Agay-Shay K. Arrebola J.P. Audouze K. Babin P.J. Barouki R. Bansal A. Blanc E. Cave M.C. Obesity II: Establishing causal links between chemical exposures and obesity Biochem. Pharmacol. 2022 199 115015 10.1016/j.bcp.2022.115015 35395240 PMC9124454

29. González-Muniesa P. Mártinez-González M.A. Hu F.B. Després J.P. Matsuzawa Y. Loos R.J.F. Moreno L.A. Bray G.A. Martinez J.A. Obesity Nat. Rev. Dis. Primers 2017 3 17034 10.1038/nrdp.2017.34 28617414

30. Pomahacova R. Paterova P. Nykodymova E. Polak P. Sladkova E. Skalicka E. Sykora J. Overweight and obesity in children and adolescents with endocrine disorders Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czechoslov. 2023 167 1 7 10.5507/bp.2023.036 37712247

31. Yu Y. Yu L. Cheng N. Liu X. Fang C. Liu S. Zhu L. Exercise Alleviates the Apolipoprotein A5-Toll-Like Receptor 4 Axis Impairment in Mice with High-Fat Diet-Induced Non-alcoholic Steatohepatitis Front. Physiol. 2021 12 783341 10.3389/fphys.2021.783341 35035359 PMC8758581

32. Liu X. Wang H. Zhu L. Profound perturbations are found in the proteome and metabolome in children with obesity after weight loss intervention Heliyon 2024 10 e31917 10.1016/j.heliyon.2024.e31917 38867950 PMC11167357

33. Yeh T.L. Hsu H.Y. Tsai M.C. Hsu L.Y. Hwang L.C. Chien K.L. Association between metabolically healthy obesity/overweight and cardiovascular disease risk: A representative cohort study in Taiwan PLoS ONE 2021 16 e0246378 10.1371/journal.pone.0246378 33524067 PMC7850496

34. Koenen M. Hill M.A. Cohen P. Sowers J.R. Obesity, Adipose Tissue and Vascular Dysfunction Circ. Res. 2021 128 951 968 10.1161/CIRCRESAHA.121.318093 33793327 PMC8026272

35. Giordani I. Malandrucco I. Picconi F. Longo S. Di Flaviani A. Chioma L. Moscatelli B. Donno S. Frontoni S. Preliminary evidence that obese patients with obstructive sleep apnea/hypopnea syndrome are refractory to the acute beneficial metabolic effects of a very low calorie diet Acta Diabetol. 2013 50 639 643 10.1007/s00592-013-0487-5 23740164

36. Scartabelli G. Querci G. Marconi L. Ceccarini G. Piaggi P. Fierabracci P. Salvetti G. Cizza G. Mazzeo S. Vitti J. Liver Enlargement Predicts Obstructive Sleep Apnea-Hypopnea Syndrome in Morbidly Obese Women Front. Endocrinol. 2018 9 293 10.3389/fendo.2018.00293 PMC5998798 29928260

37. Xu Z. Jiaqing A. Yuchuan L. Shen K. A case-control study of obstructive sleep apnea-hypopnea syndrome in obese and nonobese chinese children Chest 2008 133 684 689 10.1378/chest.07-1611 18198258

38. Ming X. Yang M. Chen X. Metabolic bariatric surgery as a treatment for obstructive sleep apnea hypopnea syndrome: Review of the literature and potential mechanisms Surg. Obes. Relat. Dis. Off. J. Am. Soc. Bariatr. Surg. 2021 17 215 220 10.1016/j.soard.2020.09.019 33371935

39. Dehlin M. Jacobsson L. Roddy E. Global epidemiology of gout: Prevalence, incidence, treatment patterns and risk factors Nat. Rev. Rheumatol. 2020 16 380 390 10.1038/s41584-020-0441-1 32541923

40. Larsson S.C. Burgess S. Michaëlsson K. Genetic association between adiposity and gout: A Mendelian randomization study Rheumatology 2018 57 2145 2148 10.1093/rheumatology/key229 30085130 PMC6697177

41. Korkmaz H.A. Özkan B. Impact of Obesity on Bone Metabolism in Children J. Pediatr. Endocrinol. Metab. JPEM 2022 35 557 565 10.1515/jpem-2021-0714 35393850

42. Zlotnik A. Yoshie O. Chemokines: A new classification system and their role in immunity Immunity 2000 12 121 127 10.1016/S1074-7613(00)80165-X 10714678

43. Hughes C.E. Nibbs R.J.B. A guide to chemokines and their receptors FEBS J. 2018 285 2944 2971 10.1111/febs.14466 29637711 PMC6120486

44. Mantovani A. The chemokine system: Redundancy for robust outputs Immunol. Today 1999 20 254 257 10.1016/S0167-5699(99)01469-3 10354549

45. Zlotnik A. Yoshie O. The chemokine superfamily revisited Immunity 2012 36 705 716 10.1016/j.immuni.2012.05.008 22633458 PMC3396424

46. Luster A.D. Chemokines--chemotactic cytokines that mediate inflammation N. Engl. J. Med. 1998 338 436 445 10.1056/NEJM199802123380706 9459648

47. Charo I.F. Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation N. Engl. J. Med. 2006 354 610 621 10.1056/NEJMra052723 16467548

48. Korbecki J. Kojder K. Kapczuk P. Kupnicka P. Gawronska-Szklarz B. Gutowska I. Chlubek D. Baranowska-Bosiacka I. The Effect of Hypoxia on the Expression of CXC Chemokines and CXC Chemokine Receptors-A Review of Literature Int. J. Mol. Sci. 2021 22 843 10.3390/ijms22020843 33467722 PMC7830156

49. Xue W. Fan Z. Li L. Lu J. Zhai Y. Zhao J. The chemokine system and its role in obesity J. Cell. Physiol. 2019 234 3336 3346 10.1002/jcp.27293 30375006

50. Wasmuth H.E. Tacke F. Trautwein C. Chemokines in liver inflammation and fibrosis Semin. Liver Dis. 2010 30 215 225 10.1055/s-0030-1255351 20665374

51. Ullah A. Ud Din A. Ding W. Shi Z. Pervaz S. Shen B. A narrative review: CXC chemokines influence immune surveillance in obesity and obesity-related diseases: Type 2 diabetes and nonalcoholic fatty liver disease Rev. Endocr. Metab. Disord. 2023 24 611 631 10.1007/s11154-023-09800-w 37000372 PMC10063956

52. Straczkowski M. Kowalska I. Nikolajuk A. Dzienis-Straczkowska S. Szelachowska M. Kinalska I. Plasma interleukin 8 concentrations in obese subjects with impaired glucose tolerance Cardiovasc. Diabetol. 2003 2 5 10.1186/1475-2840-2-5 12793907 PMC162167

53. Mortier A. Berghmans N. Ronsse I. Grauwen K. Stegen S. Van Damme J. Proost P. Biological Activity of CXCL8 Forms Generated by Alternative Cleavage of the Signal Peptide or by Aminopeptidase-Mediated Truncation PLoS ONE 2011 6 9 10.1371/journal.pone.0023913 21904597 PMC3164136

54. Lin C. He H. Liu H. Li R. Chen Y. Qi Y. Jiang Q. Chen L. Zhang P. Zhang H. Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer Gut 2019 68 1764 1773 10.1136/gutjnl-2018-316324 30661053

55. Ha H. Debnath B. Neamati N. Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases Theranostics 2017 7 1543 1588 10.7150/thno.15625 28529637 PMC5436513

56. Bruun J.M. Pedersen S.B. Richelsen B. Interleukin-8 production in human adipose tissue. inhibitory effects of anti-diabetic compounds, the thiazolidinedione ciglitazone and the biguanide metformin Horm. Metab. Res. 2000 32 537 541 10.1055/s-2007-978682 11246821

57. Cambier S. Gouwy M. Proost P. The chemokines CXCL8 and CXCL12: Molecular and functional properties, role in disease and efforts towards pharmacological intervention Cell. Mol. Immunol. 2023 20 217 251 10.1038/s41423-023-00974-6 36725964 PMC9890491

58. Alfaro C. Sanmamed M.F. Rodríguez-Ruiz M.E. Teijeira A. Oñate C. González A. Ponz M. Schalper K.A. Pérez-Gracia J.L. Melero I. Interleukin-8 in cancer pathogenesis, treatment and follow-up Cancer Treat. Rev. 2017 60 24 31 10.1016/j.ctrv.2017.08.004 28866366

59. Lima R.S. Mattos R.T. Medeiros N.I. Kattah F.M. Nascimento J.R.S. Menezes C.A. Rios-Santos F. Dutra W.O. Gomes J.A.S. Moreira P.R. CXCL8 expression and methylation are correlated with anthropometric and metabolic parameters in childhood obesity Cytokine 2021 143 155538 10.1016/j.cyto.2021.155538 33926776

60. Trellakis S. Rydleuskaya A. Fischer C. Canbay A. Tagay S. Scherag A. Bruderek K. Schuler P.J. Brandau S. Low adiponectin, high levels of apoptosis and increased peripheral blood neutrophil activity in healthy obese subjects Obes. Facts 2012 5 305 318 10.1159/000339452 22722748

61. Costa A. van der Stelt I. Reynés B. Konieczna J. Fiol M. Keijer J. Palou A. Romaguera D. van Schothorst E.M. Oliver P. Whole-Genome Transcriptomics of PBMC to Identify Biomarkers of Early Metabolic Risk in Apparently Healthy People with Overweight-Obesity and in Normal-Weight Subjects Mol. Nutr. Food Res. 2023 67 e2200503 10.1002/mnfr.202200503 36564895

62. Wijtmans M. Scholten D. Mooij W. Smit M.J. de Esch I.J.P. de Graaf C. Leurs R. Exploring the CXCR3 Chemokine Receptor with Small-Molecule Antagonists and Agonists Chemokines: Chemokines and Their Receptors in Drug Discovery Tschammer N. Springer International Publishing Ag Cham, Switzerland 2015 Volume 14 119 185

63. Vielma S.A. Klein R.L. Levingston C.A. Young M.R. Adipocytes as immune regulatory cells Int. Immunopharmacol. 2013 16 224 231 10.1016/j.intimp.2013.04.002 23587489 PMC3752601

64. Fukuda Y. Asaoka T. Eguchi H. Yokota Y. Kubo M. Kinoshita M. Urakawa S. Iwagami Y. Tomimaru Y. Akita H. Endogenous CXCL9 affects prognosis by regulating tumor-infiltrating natural killer cells in intrahepatic cholangiocarcinoma Cancer Sci. 2020 111 323 333 10.1111/cas.14267 31799781 PMC7004525

65. Frigerio S. Junt T. Lu B. Gerard C. Zumsteg U. Holländer G.A. Piali L. Beta cells are responsible for CXCR3-mediated T-cell infiltration in insulitis Nat. Med. 2002 8 1414 1420 10.1038/nm1202-792 12415259

66. House I.G. Savas P. Lai J.Y. Chen A.X.Y. Oliver A.J. Teo Z.L. Todd K.L. Henderson M.A. Giuffrida L. Petley E.V. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade Clin. Cancer Res. 2020 26 487 504 10.1158/1078-0432.CCR-19-1868 31636098

67. Sadeghian-Rizi T. Behdani M. Khanahmad H. Ghasemi-Dehkordi P. Sadeghi H.M. Jahanian-Najafabadi A. Production of Novel Camelid Anti-CXCL10 Specific Polyclonal Antibodies and Evaluation of Their Bioreactivity Int. J. Pept. Res. Ther. 2019 25 535 540 10.1007/s10989-018-9697-6

68. Nigi L. Brusco N. Grieco G.E. Licata G. Krogvold L. Marselli L. Gysemans C. Overbergh L. Marchetti P. Mathieu C. Pancreatic Alpha-Cells Contribute Together with Beta-Cells to CXCL10 Expression in Type 1 Diabetes Front. Endocrinol. 2020 11 630 10.3389/fendo.2020.00630 PMC7523508 33042009

69. Antonelli A. Ferrari S.M. Giuggioli D. Ferrannini E. Ferri C. Fallahi P. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases Autoimmun. Rev. 2014 13 272 280 10.1016/j.autrev.2013.10.010 24189283

70. Moreno B. Hueso L. Ortega R. Benito E. Martínez-Hervas S. Peiro M. Civera M. Sanz M.J. Piqueras L. Real J.T. Association of chemokines IP-10/CXCL10 and I-TAC/CXCL11 with insulin resistance and enhance leukocyte endothelial arrest in obesity Microvasc. Res. 2022 139 104254 10.1016/j.mvr.2021.104254 34534571

71. Kochumon S. Madhoun A.A. Al-Rashed F. Azim R. Al-Ozairi E. Al-Mulla F. Ahmad R. Adipose tissue gene expression of CXCL10 and CXCL11 modulates inflammatory markers in obesity: Implications for metabolic inflammation and insulin resistance Ther. Adv. Endocrinol. Metab. 2020 11 2042018820930902 10.1177/2042018820930902 32655851 PMC7331767

72. Yang X.Y. Ozawa S. Kato Y. Maehata Y. Izukuri K. Ikoma T. Kanamori K. Akasaka T. Suzuki K. Iwabuchi H. C-X-C Motif Chemokine Ligand 14 is a Unique Multifunctional Regulator of Tumor Progression Int. J. Mol. Sci. 2019 20 1872 10.3390/ijms20081872 31014014 PMC6514660

73. Meuter S. Moser B. Constitutive expression of CXCL14 in healthy human and murine epithelial tissues Cytokine 2008 44 248 255 10.1016/j.cyto.2008.08.009 18809336

74. Matsushita Y. Hasegawa Y. Takebe N. Onodera K. Shozushima M. Oda T. Nagasawa K. Honma H. Nata K. Sasaki A. Serum C-X-C motif chemokine ligand 14 levels are associated with serum C-peptide and fatty liver index in type 2 diabetes mellitus patients J. Diabetes Investig. 2021 12 1042 1049 10.1111/jdi.13438 33063457 PMC8169342

75. Cereijo R. Quesada-López T. Gavaldà-Navarro A. Tarascó J. Pellitero S. Reyes M. Puig-Domingo M. Giralt M. Sánchez-Infantes D. Villarroya F. The chemokine CXCL14 is negatively associated with obesity and concomitant type-2 diabetes in humans Int. J. Obes. (2005) 2021 45 706 710 10.1038/s41366-020-00732-y 33414488

76. Korbecki J. Kojder K. Simińska D. Bohatyrewicz R. Gutowska I. Chlubek D. Baranowska-Bosiacka I. CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of the Ligands of Receptors CCR1, CCR2, CCR3, and CCR4 Int. J. Mol. Sci. 2020 21 8412 10.3390/ijms21218412 33182504 PMC7665155

77. Korbecki J. Grochans S. Gutowska I. Barczak K. Baranowska-Bosiacka I. CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands Int. J. Mol. Sci. 2020 21 7619 10.3390/ijms21207619 33076281 PMC7590012

78. Korbecki J. Kojder K. Barczak K. Simińska D. Gutowska I. Chlubek D. Baranowska-Bosiacka I. Hypoxia Alters the Expression of CC Chemokines and CC Chemokine Receptors in a Tumor-A Literature Review Int. J. Mol. Sci. 2020 21 5647 10.3390/ijms21165647 32781743 PMC7460668

79. Huber J. Kiefer F.W. Zeyda M. Ludvik B. Silberhumer G.R. Prager G. Zlabinger G.J. Stulnig T.M. CC chemokine and CC chemokine receptor profiles in visceral and subcutaneous adipose tissue are altered in human obesity J. Clin. Endocrinol. Metab. 2008 93 3215 3221 10.1210/jc.2007-2630 18492752

80. Xia M. Sui Z. Recent developments in CCR2 antagonists Expert Opin. Ther. Pat. 2009 19 295 303 10.1517/13543770902755129 19441905

81. Matsushima K. Larsen C.G. DuBois G.C. Oppenheim J.J. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line J. Exp. Med. 1989 169 1485 1490 10.1084/jem.169.4.1485 2926331 PMC2189236

82. Huma Z.E. Sanchez J. Lim H.D. Bridgford J.L. Huang C. Parker B.J. Pazhamalil J.G. Porebski B.T. Pfleger K.D.G. Lane J.R. Key determinants of selective binding and activation by the monocyte chemoattractant proteins at the chemokine receptor CCR2 Sci. Signal. 2017 10 eaai8529 10.1126/scisignal.aai8529 28536301

83. Gschwandtner M. Derler R. Midwood K.S. More Than Just Attractive: How CCL2 Influences Myeloid Cell Behavior Beyond Chemotaxis Front. Immunol. 2019 10 2759 10.3389/fimmu.2019.02759 31921102 PMC6923224

84. Chistiakov D.A. Melnichenko A.A. Grechko A.V. Myasoedova V.A. Orekhov A.N. Potential of anti-inflammatory agents for treatment of atherosclerosis Exp. Mol. Pathol. 2018 104 114 124 10.1016/j.yexmp.2018.01.008 29378168

85. Singh S. Anshita D. Ravichandiran V. MCP-1: Function, regulation, and involvement in disease Int. Immunopharmacol. 2021 101 10 10.1016/j.intimp.2021.107598 34233864 PMC8135227

86. Arner E. Mejhert N. Kulyté A. Balwierz P.J. Pachkov M. Cormont M. Lorente-Cebrián S. Ehrlund A. Laurencikiene J. Hedén P. Adipose tissue microRNAs as regulators of CCL2 production in human obesity Diabetes 2012 61 1986 1993 10.2337/db11-1508 22688341 PMC3402332

87. Akhter N. Kochumon S. Hasan A. Wilson A. Nizam R. Al Madhoun A. Al-Rashed F. Arefanian H. Alzaid F. Sindhu S. IFN-γ and LPS Induce Synergistic Expression of CCL2 in Monocytic Cells via H3K27 Acetylation J. Inflamm. Res. 2022 15 4291 4302 10.2147/JIR.S368352 35923906 PMC9343018

88. Riddy D.M. Kammoun H.L. Murphy A.J. Bosnyak-Gladovic S. De la Fuente Gonzalez R. Merlin J. Ziemann M. Fabb S. Pierce T.L. Diepenhorst N. Deletion of GPR21 improves glucose homeostasis and inhibits the CCL2-CCR2 axis by divergent mechanisms BMJ Open Diabetes Res. Care 2021 9 e002285 10.1136/bmjdrc-2021-002285 PMC8593704 34782333

89. Fink L.N. Costford S.R. Lee Y.S. Jensen T.E. Bilan P.J. Oberbach A. Blüher M. Olefsky J.M. Sams A. Klip A. Pro-inflammatory macrophages increase in skeletal muscle of high fat-fed mice and correlate with metabolic risk markers in humans Obesity 2014 22 747 757 10.1002/oby.20615 24030890

90. Ottonello L. Montecucco F. Bertolotto M. Arduino N. Mancini M. Corcione A. Pistoia V. Dallegri F. CCL3 (MIP-1alpha) induces in vitro migration of GM-CSF-primed human neutrophils via CCR5-dependent activation of ERK 1/2 Cell. Signal. 2005 17 355 363 10.1016/j.cellsig.2004.08.002 15567066

91. Kang T.G. Park H.J. Moon J. Lee J.H. Ha S.J. Enriching CCL3 in the Tumor Microenvironment Facilitates T cell Responses and Improves the Efficacy of Anti-PD-1 Therapy Immune Netw. 2021 21 e23 10.4110/in.2021.21.e23 34277113 PMC8263215

92. Guan B. Li H. Yao J. Guo J. Yu F. Li G. Wan B. Ma J. Huang D. Sun L. CCL3-CCR5 axis promotes cell migration and invasion of colon adenocarcinoma via Akt signaling pathway Environ. Toxicol. 2023 38 172 184 10.1002/tox.23675 36346222

93. Bala M. Kopp A. Wurm S. Büchler C. Schölmerich J. Schäffler A. Type 2 diabetes and lipoprotein metabolism affect LPS-induced cytokine and chemokine release in primary human monocytes Exp. Clin. Endocrinol. Diabetes Off. J. Ger. Soc. Endocrinol. Ger. Diabetes Assoc. 2011 119 370 376 10.1055/s-0030-1268413 21104588

94. Kochumon S. Arefanian H. Azim R. Shenouda S. Jacob T. Abu Khalaf N. Al-Rashed F. Hasan A. Sindhu S. Al-Mulla F. Stearic Acid and TNF-α Co-Operatively Potentiate MIP-1α Production in Monocytic Cells via MyD88 Independent TLR4 /TBK/IRF3 Signaling Pathway Biomedicines 2020 8 403 10.3390/biomedicines8100403 33050324 PMC7600458

95. Pisano S. Catone G. Coppola G. Carotenuto M. Iuliano R. Tiano C. Montesanto A.R. D’Esposito V. Miraglia Del Giudice E. Formisano P. Different Immune Signature in Youths Experiencing Antipsychotic-Induced Weight Gain Compared to Untreated Obese Patients J. Child Adolesc. Psychopharmacol. 2017 27 844 848 10.1089/cap.2016.0203 28453334

96. Hu A. Zhu J. Zeng C. Lin C.H. Yu J. Liu J.Q. Lynch K. Talebian F. Pan X. Yan J. IL-27 Induces CCL5 Production by T Lymphocytes, Which Contributes to Antitumor Activity J. Immunol. 2022 208 2239 2245 10.4049/jimmunol.2100885 35418466 PMC9050872

97. Chou S.Y. Ajoy R. Changou C.A. Hsieh Y.T. Wang Y.K. Hoffer B. CCL5/RANTES contributes to hypothalamic insulin signaling for systemic insulin responsiveness through CCR5 Sci. Rep. 2016 6 37659 10.1038/srep37659 27898058 PMC5127185

98. Kitade H. Sawamoto K. Nagashimada M. Inoue H. Yamamoto Y. Sai Y. Takamura T. Yamamoto H. Miyamoto K. Ginsberg H.N. CCR5 plays a critical role in obesity-induced adipose tissue inflammation and insulin resistance by regulating both macrophage recruitment and M1/M2 status Diabetes 2012 61 1680 1690 10.2337/db11-1506 22474027 PMC3379680

99. Xie C. Ye F. Zhang N. Huang Y. Pan Y. Xie X. CCL7 contributes to angiotensin II-induced abdominal aortic aneurysm by promoting macrophage infiltration and pro-inflammatory phenotype J. Cell. Mol. Med. 2021 25 7280 7293 10.1111/jcmm.16757 34189838 PMC8335673

100. Liu Y. Cai Y. Liu L. Wu Y. Xiong X. Crucial biological functions of CCL7 in cancer PeerJ 2018 6 e4928 10.7717/peerj.4928 29915688 PMC6004300

101. Chang T.T. Chen C. Chen J.W. CCL7 as a novel inflammatory mediator in cardiovascular disease, diabetes mellitus, and kidney disease Cardiovasc. Diabetol. 2022 21 185 10.1186/s12933-022-01626-1 36109744 PMC9479413

102. Luo Z.H. Niu M.W. Gong S.H. Wu G.Y. Wang T. Wang F.Z. Wei G.Q. He Z.K. Jiang Y. Chen P. Intestinal epithelial chemokine (C-C motif) ligand 7 overexpression protects against high fat diet-induced obesity and hepatic steatosis in mice Chin. Med. J. 2020 133 1805 1814 10.1097/CM9.0000000000000915 32649507 PMC7469995

103. Liddle D.M. Monk J.M. Hutchinson A.L. Ma D.W.L. Robinson L.E. CD8(+) T cell/adipocyte inflammatory cross talk and ensuing M1 macrophage polarization are reduced by fish-oil-derived n-3 polyunsaturated fatty acids, in part by a TNF-α-dependent mechanism J. Nutr. Biochem. 2020 76 108243 10.1016/j.jnutbio.2019.108243 31760229

104. Schlesinger S. Herder C. Kannenberg J.M. Huth C. Carstensen-Kirberg M. Rathmann W. Bönhof G.J. Koenig W. Heier M. Peters A. General and Abdominal Obesity and Incident Distal Sensorimotor Polyneuropathy: Insights Into Inflammatory Biomarkers as Potential Mediators in the KORA F4/FF4 Cohort Diabetes Care 2019 42 240 247 10.2337/dc18-1842 30523031

105. Nomiyama H. Hieshima K. Osada N. Kato-Unoki Y. Otsuka-Ono K. Takegawa S. Izawa T. Yoshizawa A. Kikuchi Y. Tanase S. Extensive expansion and diversification of the chemokine gene family in zebrafish: Identification of a novel chemokine subfamily CX BMC Genom. 2008 9 222 10.1186/1471-2164-9-222 PMC2416438 18482437

106. Kroczek A.L. Hartung E. Gurka S. Becker M. Reeg N. Mages H.W. Voigt S. Freund C. Kroczek R.A. Structure-Function Relationship of XCL1 Used for in vivo Targeting of Antigen Into XCR1(+) Dendritic Cells Front. Immunol. 2018 9 2806 10.3389/fimmu.2018.02806 30619244 PMC6300513

107. Guzzo C. Fox J. Lin Y. Miao H. Cimbro R. Volkman B.F. Fauci A.S. Lusso P. The CD8-derived chemokine XCL1/lymphotactin is a conformation-dependent, broad-spectrum inhibitor of HIV-1 PLoS Pathog. 2013 9 e1003852 10.1371/journal.ppat.1003852 24385911 PMC3873461

108. Dong C. Chua A. Ganguly B. Krensky A.M. Clayberger C. Glycosylated recombinant human XCL1/lymphotactin exhibits enhanced biologic activity J. Immunol. Methods 2005 302 136 144 10.1016/j.jim.2005.05.008 15992811

109. Matsuo K. Kitahata K. Kawabata F. Kamei M. Hara Y. Takamura S. Oiso N. Kawada A. Yoshie O. Nakayama T. A Highly Active Form of XCL1/Lymphotactin Functions as an Effective Adjuvant to Recruit Cross-Presenting Dendritic Cells for Induction of Effector and Memory CD8(+) T Cells Front. Immunol. 2018 9 2775 10.3389/fimmu.2018.02775 30542351 PMC6277777

110. Nevins A.M. Subramanian A. Tapia J.L. Delgado D.P. Tyler R.C. Jensen D.R. Ouellette A.J. Volkman B.F. A Requirement for Metamorphic Interconversion in the Antimicrobial Activity of Chemokine XCL1 Biochemistry 2016 55 3784 3793 10.1021/acs.biochem.6b00353 27305837 PMC6956654

111. Lei Y. Takahama Y. XCL1 and XCR1 in the immune system Microbes Infect. 2012 14 262 267 10.1016/j.micinf.2011.10.003 22100876

112. Wang N. Guo J. Liu F. Wang M. Li C. Jia L. Zhai L. Wei W. Bai Y. Depot-specific inflammation with decreased expression of ATM2 in white adipose tissues induced by high-margarine/lard intake PLoS ONE 2017 12 e0188007 10.1371/journal.pone.0188007 29141038 PMC5687764

113. Gil A. María Aguilera C. Gil-Campos M. Cañete R. Altered signalling and gene expression associated with the immune system and the inflammatory response in obesity Br. J. Nutr. 2007 98 (Suppl S1) S121 S126 10.1017/S0007114507838050 17922949

114. Rakotoarivelo V. Variya B. Langlois M.F. Ramanathan S. Chemokines in human obesity Cytokine 2020 127 154953 10.1016/j.cyto.2019.154953 31865065

115. Yan L. Graef G.L. Claycombe K.J. Johnson L.K. Effects of voluntary running and soy supplementation on diet-induced metabolic disturbance and inflammation in mice J. Agric. Food Chem. 2013 61 9373 9379 10.1021/jf401588h 24011182

116. Fu C.P. Sheu W.H. Lee I.T. Lee W.J. Wang J.S. Liang K.W. Lee W.L. Lin S.Y. Weight loss reduces serum monocyte chemoattractant protein-1 concentrations in association with improvements in renal injury in obese men with metabolic syndrome Clin. Chem. Lab. Med. 2015 53 623 629 10.1515/cclm-2014-0468 25301674

117. Rivera P. Martos-Moreno G. Barrios V. Suárez J. Pavón F.J. Chowen J.A. Rodríguez de Fonseca F. Argente J. A novel approach to childhood obesity: Circulating chemokines and growth factors as biomarkers of insulin resistance Pediatr. Obes. 2019 14 e12473 10.1111/ijpo.12473 30350467

118. Guo L.Y. Yang F. Peng L.J. Li Y.B. Wang A.P. CXCL2, a new critical factor and therapeutic target for cardiovascular diseases Clin. Exp. Hypertens. 2020 42 428 437 10.1080/10641963.2019.1693585 31752549

119. Kalaoja M. Corbin L.J. Tan V.Y. Ahola-Olli A.V. Havulinna A.S. Santalahti K. Pitkänen N. Lehtimäki T. Lyytikäinen L.P. Raitoharju E. The Role of Inflammatory Cytokines as Intermediates in the Pathway from Increased Adiposity to Disease Obesity 2021 29 428 437 10.1002/oby.23060 33491305 PMC8614117

120. Guria S. Hoory A. Das S. Chattopadhyay D. Mukherjee S. Adipose tissue macrophages and their role in obesity-associated insulin resistance: An overview of the complex dynamics at play Biosci. Rep. 2023 43 BSR20220200 10.1042/BSR20220200 36718668 PMC10011338

121. Kim D. Kim J. Yoon J.H. Ghim J. Yea K. Song P. Park S. Lee A. Hong C.P. Jang M.S. CXCL12 secreted from adipose tissue recruits macrophages and induces insulin resistance in mice Diabetologia 2014 57 1456 1465 10.1007/s00125-014-3237-5 24744121

122. Chan P.C. Hsieh P.S. The Chemokine Systems at the Crossroads of Inflammation and Energy Metabolism in the Development of Obesity Int. J. Mol. Sci. 2021 22 3528 10.3390/ijms222413528 34948325 PMC8709111

123. Pedersen L. Olsen C.H. Pedersen B.K. Hojman P. Muscle-derived expression of the chemokine CXCL1 attenuates diet-induced obesity and improves fatty acid oxidation in the muscle Am. J. Physiol. Endocrinol. Metab. 2012 302 E831 E840 10.1152/ajpendo.00339.2011 22275756

124. Kang Y.S. Cha J.J. Hyun Y.Y. Cha D.R. Novel C-C chemokine receptor 2 antagonists in metabolic disease: A review of recent developments Expert Opin. Investig. Drugs 2011 20 745 756 10.1517/13543784.2011.575359 21466412

125. Tamura Y. Sugimoto M. Murayama T. Minami M. Nishikaze Y. Ariyasu H. Akamizu T. Kita T. Yokode M. Arai H. C-C chemokine receptor 2 inhibitor improves diet-induced development of insulin resistance and hepatic steatosis in mice J. Atheroscler. Thromb. 2010 17 219 228 10.5551/jat.3368 20179360

126. Tamura Y. Sugimoto M. Murayama T. Ueda Y. Kanamori H. Ono K. Ariyasu H. Akamizu T. Kita T. Yokode M. Inhibition of CCR2 ameliorates insulin resistance and hepatic steatosis in db/db mice Arterioscler. Thromb. Vasc. Biol. 2008 28 2195 2201 10.1161/ATVBAHA.108.168633 18818420

127. Krenkel O. Puengel T. Govaere O. Abdallah A.T. Mossanen J.C. Kohlhepp M. Liepelt A. Lefebvre E. Luedde T. Hellerbrand C. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis Hepatology 2018 67 1270 1283 10.1002/hep.29544 28940700

128. Chang T.T. Chen J.W. Direct CCL4 Inhibition Modulates Gut Microbiota, Reduces Circulating Trimethylamine N-Oxide, and Improves Glucose and Lipid Metabolism in High-Fat-Diet-Induced Diabetes Mellitus J. Inflamm. Res. 2021 14 6237 6250 10.2147/JIR.S343491 34866923 PMC8637434

129. Sun L. Zhang Y. Cai J. Rimal B. Rocha E.R. Coleman J.P. Zhang C. Nichols R.G. Luo Y. Kim B. Bile salt hydrolase in non-enterotoxigenic Bacteroides potentiates colorectal cancer Nat. Commun. 2023 14 755 10.1038/s41467-023-36089-9 36765047 PMC9918522

130. Sundaram S. Yan L. Adipose monocyte chemotactic protein-1 deficiency reduces high-fat diet-enhanced mammary tumorigenesis in MMTV-PyMT mice J. Nutr. Biochem. 2020 77 108313 10.1016/j.jnutbio.2019.108313 31837540

131. Yao L. Heuser-Baker J. Herlea-Pana O. Zhang N. Szweda L.I. Griffin T.M. Barlic-Dicen J. Deficiency in adipocyte chemokine receptor CXCR4 exacerbates obesity and compromises thermoregulatory responses of brown adipose tissue in a mouse model of diet-induced obesity FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2014 28 4534 4550 10.1096/fj.14-249797 PMC4202106 25016030

132. Benson T.W. Weintraub D.S. Crowe M. Yiew N.K.H. Popoola O. Pillai A. Joseph J. Archer K. Greenway C. Chatterjee T.K. Deletion of the Duffy antigen receptor for chemokines (DARC) promotes insulin resistance and adipose tissue inflammation during high fat feeding Mol. Cell. Endocrinol. 2018 473 79 88 10.1016/j.mce.2018.01.006 29341885 PMC6045443

133. Zhou H. Liao X. Zeng Q. Zhang H. Song J. Hu W. Sun X. Ding Y. Wang D. Xiao Y. Metabolic effects of CCL5 deficiency in lean and obese mice Front. Immunol. 2022 13 1059687 10.3389/fimmu.2022.1059687 36713454 PMC9880418

134. Lee S.J. Kang J.S. Kim H.M. Lee E.S. Lee J.H. Chung C.H. Lee E.Y. CCR2 knockout ameliorates obesity-induced kidney injury through inhibiting oxidative stress and ER stress PLoS ONE 2019 14 e0222352 10.1371/journal.pone.0222352 31498850 PMC6733486

135. Blüher M. Obesity: Global epidemiology and pathogenesis Nat. Rev. Endocrinol. 2019 15 288 298 10.1038/s41574-019-0176-8 30814686

136. Thompson P.D. Arena R. Riebe D. Pescatello L.S. ACSM’s new preparticipation health screening recommendations from ACSM’s guidelines for exercise testing and prescription, ninth edition Curr. Sports Med. Rep. 2013 12 215 217 10.1249/JSR.0b013e31829a68cf 23851406

137. Mezzani A. Hamm L.F. Jones A.M. McBride P.E. Moholdt T. Stone J.A. Urhausen A. Williams M.A. Aerobic exercise intensity assessment and prescription in cardiac rehabilitation: A joint position statement of the European Association for Cardiovascular Prevention and Rehabilitation, the American Association of Cardiovascular and Pulmonary Rehabilitation and the Canadian Association of Cardiac Rehabilitation Eur. J. Prev. Cardiol. 2013 20 442 467 10.1177/2047487312460484 23104970

138. Félix-Soriano E. Sáinz N. Gil-Iturbe E. Castilla-Madrigal R. Celay J. Fernández-Galilea M. Pejenaute Á. Lostao M.P. Martínez-Climent J.A. Moreno-Aliaga M.J. Differential remodeling of subcutaneous white and interscapular brown adipose tissue by long-term exercise training in aged obese female mice J. Physiol. Biochem. 2023 79 451 465 10.1007/s13105-023-00964-2 37204588 PMC10300187

139. Komori T. Morikawa Y. Essential roles of the cytokine oncostatin M in crosstalk between muscle fibers and immune cells in skeletal muscle after aerobic exercise J. Biol. Chem. 2022 298 102686 10.1016/j.jbc.2022.102686 36370846 PMC9720348

140. Lacerda D.R. Moraes M.M. Nunes-Silva A. Costa K.A. Rodrigues D.F. Sabino J.L. Cordeiro L.M.S. Pinho V. Teixeira M.M. Wanner S.P. Aerobic training reduces immune cell recruitment and cytokine levels in adipose tissue in obese mice Appl. Physiol. Nutr. Metab. 2019 44 512 520 10.1139/apnm-2018-0523 30304638

141. Heo J.W. No M.H. Cho J. Choi Y. Cho E.J. Park D.H. Kim T.W. Kim C.J. Seo D.Y. Han J. Moderate aerobic exercise training ameliorates impairment of mitochondrial function and dynamics in skeletal muscle of high-fat diet-induced obese mice FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2021 35 e21340 10.1096/fj.202002394R 33455027

142. Armstrong A. Jungbluth Rodriguez K. Sabag A. Mavros Y. Parker H.M. Keating S.E. Johnson N.A. Effect of aerobic exercise on waist circumference in adults with overweight or obesity: A systematic review and meta-analysis Obes. Rev. Off. J. Int. Assoc. Study Obes. 2022 23 e13446 10.1111/obr.13446 35383401 PMC9540641

143. Berge J. Hjelmesaeth J. Hertel J.K. Gjevestad E. Småstuen M.C. Johnson L.K. Martins C. Andersen E. Helgerud J. Støren Ø. Effect of Aerobic Exercise Intensity on Energy Expenditure and Weight Loss in Severe Obesity-A Randomized Controlled Trial Obesity 2021 29 359 369 10.1002/oby.23078 33491314 PMC7898283

144. Kraemer W.J. Ratamess N.A. Fundamentals of resistance training: Progression and exercise prescription Med. Sci. Sports Exerc. 2004 36 674 688 10.1249/01.MSS.0000121945.36635.61 15064596

145. Ratamess N.A. Alvar B.A. Evetoch T.K. Housh T.J. Kibler W.B. Kraemer W.J. Triplett N.T. American College of Sports Medicine Position Stand Progression models in resistance training for healthy adults Med. Sci. Sports Exerc. 2009 41 687 708 10.1249/MSS.0b013e3181915670 19204579

146. Westcott W.L. Resistance training is medicine: Effects of strength training on health Curr. Sports Med. Rep. 2012 11 209 216 10.1249/JSR.0b013e31825dabb8 22777332

147. Costa J.S.R. Fonseca G. Ottone N. Silva P.A. Antonaccio R.F. Silva G. Rocha M. Coimbra C.C. Esteves E.A. Mang Z.A. Strength training improves insulin resistance and differently affects mitochondria in skeletal muscle and visceral adipose tissue in high-fat fed mice Life Sci. 2021 278 119639 10.1016/j.lfs.2021.119639 34043987

148. Melo A.B. Damiani A.P.L. Coelho P.M. de Assis A. Nogueira B.V. Guimarães Ferreira L. Leite R.D. Ribeiro Júnior R.F. Lima-Leopoldo A.P. Leopoldo A.S. Resistance training promotes reduction in Visceral Adiposity without improvements in Cardiomyocyte Contractility and Calcium handling in Obese Rats Int. J. Med. Sci. 2020 17 1819 1832 10.7150/ijms.42612 32714085 PMC7378665

149. Leite R.D. Durigan Rde C. de Souza Lino A.D. de Souza Campos M.V. Souza M. Selistre-de-Araújo H.S. Bouskela E. Kraemer-Aguiar L.G. Resistance training may concomitantly benefit body composition, blood pressure and muscle MMP-2 activity on the left ventricle of high-fat fed diet rats Metab. Clin. Exp. 2013 62 1477 1484 10.1016/j.metabol.2013.05.009 23790633

150. Kim S.W. Park H.Y. Jung W.S. Lim K. Effects of Twenty-Four Weeks of Resistance Exercise Training on Body Composition, Bone Mineral Density, Functional Fitness and Isokinetic Muscle Strength in Obese Older Women: A Randomized Controlled Trial Int. J. Environ. Res. Public Health 2022 19 4554 10.3390/ijerph192114554 36361434 PMC9656451

151. Said M.A. Abdelmoneem M. Almaqhawi A. Hamid Kotob A.A. Alibrahim M.C. Bougmiza I. Multidisciplinary approach to obesity: Aerobic or resistance physical exercise? J. Exerc. Sci. Fit. 2018 16 118 123 10.1016/j.jesf.2018.11.001 30662505 PMC6323181

152. Effting P.S. Thirupathi A. Müller A.P. Pereira B.C. Sepa-Kishi D.M. Marqueze L.F.B. Vasconcellos F.T.F. Nesi R.T. Pereira T.C.B. Kist L.W. Resistance Exercise Training Improves Metabolic and Inflammatory Control in Adipose and Muscle Tissues in Mice Fed a High-Fat Diet Nutrients 2022 14 2179 10.3390/nu14112179 35683979 PMC9182921

153. Tang L. Gao X. Yang X. Liu C. Wang X. Han Y. Zhao X. Chi A. Sun L. Ladder-Climbing Training Prevents Bone Loss and Microarchitecture Deterioration in Diet-Induced Obese Rats Calcif. Tissue Int. 2016 98 85 93 10.1007/s00223-015-0063-9 26410845

154. Dâmaso A.R. da Silveira Campos R.M. Caranti D.A. de Piano A. Fisberg M. Foschini D. de Lima Sanches P. Tock L. Lederman H.M. Tufik S. Aerobic plus resistance training was more effective in improving the visceral adiposity, metabolic profile and inflammatory markers than aerobic training in obese adolescents J. Sports Sci. 2014 32 1435 1445 10.1080/02640414.2014.900692 24730354

155. In G. Taskin H.E. Al M. Alptekin H.K. Zengin K. Yumuk V. Ikitimur B. Comparison of 12-Week Fitness Protocols Following Bariatric Surgery: Aerobic Exercise Versus Aerobic Exercise and Progressive Resistance Obes. Surg. 2021 31 1475 1484 10.1007/s11695-020-05144-5 33409974

156. Brellenthin A.G. Lee D.C. Bennie J.A. Sui X. Blair S.N. Resistance exercise, alone and in combination with aerobic exercise, and obesity in Dallas, Texas, US: A prospective cohort study PLoS Med. 2021 18 e1003687 10.1371/journal.pmed.1003687 34161329 PMC8266085

157. Villareal D.T. Aguirre L. Gurney A.B. Waters D.L. Sinacore D.R. Colombo E. Armamento-Villareal R. Qualls C. Aerobic or Resistance Exercise, or Both, in Dieting Obese Older Adults N. Engl. J. Med. 2017 376 1943 1955 10.1056/NEJMoa1616338 28514618 PMC5552187

158. van Baak M.A. Pramono A. Battista F. Beaulieu K. Blundell J.E. Busetto L. Carraça E.V. Dicker D. Encantado J. Ermolao A. Effect of different types of regular exercise on physical fitness in adults with overweight or obesity: Systematic review and meta-analyses Obes. Rev. Off. J. Int. Assoc. Study Obes. 2021 22 (Suppl. S4) e13239 10.1111/obr.13239 PMC8365680 33939229

159. García-Hermoso A. Ramírez-Vélez R. Ramírez-Campillo R. Peterson M.D. Martínez-Vizcaíno V. Concurrent aerobic plus resistance exercise versus aerobic exercise alone to improve health outcomes in paediatric obesity: A systematic review and meta-analysis Br. J. Sports Med. 2018 52 161 166 10.1136/bjsports-2016-096605 27986760

160. Muñoz J. Akhavan N.S. Mullins A.P. Arjmandi B.H. Macrophage Polarization and Osteoporosis: A Review Nutrients 2020 12 2999 10.3390/nu12102999 33007863 PMC7601854

161. Mesinovic J. Jansons P. Zengin A. de Courten B. Rodriguez A.J. Daly R.M. Ebeling P.R. Scott D. Exercise attenuates bone mineral density loss during diet-induced weight loss in adults with overweight and obesity: A systematic review and meta-analysis J. Sport Health Sci. 2021 10 550 559 10.1016/j.jshs.2021.05.001 34004388 PMC8500851

162. Yang D.-H. Yang M.-Y. The Role of Macrophage in the Pathogenesis of Osteoporosis Int. J. Mol. Sci. 2019 20 2093 10.3390/ijms20092093 31035384 PMC6539137

163. Zakharova A.N. Kironenko T.A. Milovanova K.G. Orlova A.A. Dyakova E.Y. Kalinnikova Yu G. Kabachkova A.V. Chibalin A.V. Kapilevich L.V. Treadmill Training Effect on the Myokines Content in Skeletal Muscles of Mice with a Metabolic Disorder Model Front. Physiol. 2021 12 709039 10.3389/fphys.2021.709039 34858197 PMC8631430

164. Li N. Shi H. Guo Q. Gan Y. Zhang Y. Jia J. Zhang L. Zhou Y. Aerobic Exercise Prevents Chronic Inflammation and Insulin Resistance in Skeletal Muscle of High-Fat Diet Mice Nutrients 2022 14 3730 10.3390/nu14183730 36145106 PMC9503887

165. Lee S. Libman I. Hughan K.S. Kuk J.L. Barinas-Mitchell E. Chung H. Arslanian S. Effects of exercise modality on body composition and cardiovascular disease risk factors in adolescents with obesity: A randomized clinical trial Appl. Physiol. Nutr. Metab. 2020 45 1377 1386 10.1139/apnm-2019-0993 32674587

166. Trayhurn P. Wood I.S. Adipokines: Inflammation and the pleiotropic role of white adipose tissue Br. J. Nutr. 2004 92 347 355 10.1079/BJN20041213 15469638

167. Wasinski F. Bacurau R.F. Moraes M.R. Haro A.S. Moraes-Vieira P.M. Estrela G.R. Paredes-Gamero E.J. Barros C.C. Almeida S.S. Câmara N.O. Exercise and caloric restriction alter the immune system of mice submitted to a high-fat diet Mediat. Inflamm. 2013 2013 395672 10.1155/2013/395672 PMC3610381 23576853

168. Trøseid M. Lappegård K.T. Claudi T. Damås J.K. Mørkrid L. Brendberg R. Mollnes T.E. Exercise reduces plasma levels of the chemokines MCP-1 and IL-8 in subjects with the metabolic syndrome Eur. Heart J. 2004 25 349 355 10.1016/j.ehj.2003.12.006 14984925

169. Weisberg S.P. McCann D. Desai M. Rosenbaum M. Leibel R.L. Ferrante A.W. Jr. Obesity is associated with macrophage accumulation in adipose tissue J. Clin. Investig. 2003 112 1796 1808 10.1172/JCI200319246 14679176 PMC296995

170. Kawanishi N. Mizokami T. Yano H. Suzuki K. Exercise attenuates M1 macrophages and CD8+ T cells in the adipose tissue of obese mice Med. Sci. Sports Exerc. 2013 45 1684 1693 10.1249/MSS.0b013e31828ff9c6 23954991

171. Bonecchi R. Kennedy A. Gruen M.L. Gutierrez D.A. Surmi B.K. Orr J.S. Webb C.D. Hasty A.H. Impact of Macrophage Inflammatory Protein-1α Deficiency on Atherosclerotic Lesion Formation, Hepatic Steatosis, and Adipose Tissue Expansion PLoS ONE 2012 7 e31508 10.1371/journal.pone.0031508 22359597 PMC3281060

172. Sano T. Iwashita M. Nagayasu S. Yamashita A. Shinjo T. Hashikata A. Asano T. Kushiyama A. Ishimaru N. Takahama Y. Protection from diet-induced obesity and insulin resistance in mice lacking CCL19-CCR7 signaling Obesity 2015 23 1460 1471 10.1002/oby.21127 26097021

173. Carlin J.L. Grissom N. Ying Z. Gomez-Pinilla F. Reyes T.M. Voluntary exercise blocks Western diet-induced gene expression of the chemokines CXCL10 and CCL2 in the prefrontal cortex Brain Behav. Immun. 2016 58 82 90 10.1016/j.bbi.2016.07.161 27492632 PMC5352157

174. Rajasekaran M. Sul O.J. Choi E.K. Kim J.E. Suh J.H. Choi H.S. MCP-1 deficiency enhances browning of adipose tissue via increased M2 polarization J. Endocrinol. 2019 242 91 101 10.1530/JOE-19-0190 31137011

175. van der Zalm I.J.B. van der Valk E.S. Wester V.L. Nagtzaam N.M.A. van Rossum E.F.C. Leenen P.J.M. Dik W.A. Obesity-associated T-cell and macrophage activation improve partly after a lifestyle intervention Int. J. Obes. (2005) 2020 44 1838 1850 10.1038/s41366-020-0615-6 32678324

176. Zehsaz F. Farhangi N. Mirheidari L. The effect of aerobic training on CXL5, tumor necrosis factor α and insulin resistance index (HOMA-IR) in sedentary obese women Cent. -Eur. J. Immunol. 2014 39 365 369 10.5114/ceji.2014.45949 26155149 PMC4440003

177. Ramírez-Vélez R. García-Hermoso A. Correa-Rodríguez M. Fernández-Irigoyen J. Palomino-Echeverría S. Santamaría E. Correa-Bautista J.E. González-Ruíz K. Izquierdo M. Effects of Different Doses of Exercise on Inflammation Markers Among Adolescents with Overweight/Obesity: HEPAFIT Study J. Clin. Endocrinol. Metab. 2022 107 e2619 e2627 10.1210/clinem/dgac021 35038337 PMC9472258